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Deutsche Zusammenfassung 
Hintergrund: Das "Umfassende ICF Core Set für Multiple Sklerose" dient der 
klinischen Anwendung der Internationalen Klassifikation der Funktionsfähigkeit, 
Behinderung und Gesundheit (ICF) der Weltgesundheitsorganisation (WHO) mit dem 
Ziel, die typische Bandbreite der Funktionsfähigkeit bei Patienten mit Multipler 
Sklerose abzubilden.  
Ziel: Das Ziel dieser Studie war die Validierung des "Umfassenden ICF Core Sets für 
Multiple Sklerose" aus der Perspektive der Ärzte. 
Methoden: Mit Hilfe der Delphi-Methode wurden Ärzte mit Erfahrung in der 
Behandlung von Patienten mit Multipler Sklerose nach den Problemen, Ressourcen 
und Umweltfaktoren gefragt, die für die ärztliche Behandlung ihrer Patienten eine 
Rolle spielen. Die Expertenbefragung erfolgte in drei Runden per elektronischer 
Postzustellung (E-mail). Die Antworten der ersten Runde wurden nach definierten 
Übersetzungsregeln von zwei darin geschulten Doktoranden in die Sprache der ICF 
übersetzt. Der Grad der Übereinstimmung der gelinkten Antworten wurde anhand 
des statistischen Wertes Kappa berechnet. Die ICF-Kategorien der ersten Runde 
und die Ergebnisse der zweiten Runde wurden den Teilnehmern in einem zweiten 
und dritten Fragebogen zurückgemeldet.  
Ergebnisse: Vierundachtzig Ärzte aus 36 Ländern nannten 1735 Probleme, 
Ressourcen und Umweltfaktoren, die in der Behandlung von MS Patienten eine Rolle 
spielen. 1452 davon konnten in 166 ICF-Kategorien übersetzt werden. Die restlichen 
Aussagen wurden den Personbezogenen Faktoren zugeordnet, bezeichneten eine 
spezielle Diagnose, waren nicht im ICF enthalten oder zu allgemein um sie in eine 
bestimmte ICF-Kategorie übersetzen zu können. Insgesamt wurden 89 ICF-
Kategorien (64,5%) des „Umfassenden ICF Core Set für Multiple Sklerose“ von den 
Teilnehmern bestätigt, 49 Kategorien wurden nicht benannt. Acht zusätzliche ICF-
Kategorien, die im bisherigen ICF Core Set für Multiple Sklerose nicht enthalten sind, 
wurden von mehr als 75 Prozent der teilnehmenden Ärzten als wichtig angesehen.  
Fazit: Die Validität des "Umfassenden ICF Core Set für Multiple Sklerose" wurde aus 
der Perspektive der Ärzte im Wesentlichen bestätigt. Es wurden einige  zusätzliche 
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ICF-Kategorien als wichtig erachtet, deren Aufnahme in das „Umfassende ICF Core 
Set für Multiple Sklerose“ in weiteren Studien diskutiert werden muss. 
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Abstract 
Background: The "Comprehensive ICF Core Set for Multiple Sclerosis" is an 
application of the International Classification of Functioning, Disability and Health 
(ICF) of the World Health Organisation (WHO) with the intention to represent the 
typical spectrum of functioning of patients with MS.  
Objective: The objective of this study was to validate the "Comprehensive ICF Core 
Set for Multiple Sclerosis" from the perspective of physicians. 
Methods: Using the Delphi technique physicians with experience in the treatment of 
patients with Multiple Sclerosis were requested to name MS patients` problems, 
resources and aspects of environment treated by physicians. The three-round survey 
was performed by electronic-mail (e-mail). Based on established linking rules the 
statements of the first Delphi round were linked to ICF categories by two trained 
doctoral students. The level of agreement was calculated by using the statistical 
value Kappa. The ICF categories of round one as well as the results of round two 
were reported back to the participants. 
Results: Eighty-four physicians out of 36 countries named 1735 problems, resources 
and aspects of environment that are important in the treatment of patients with 
multiple sclerosis. There from 1452 could be linked to 166 ICF categories. The 
remaining statements were allotted to the component Personal Factors, indicated a 
definite diagnosis, were not classified in the ICF or were to general to define it clearly 
in the ICF. Totally, 89 categories (64.5 %) of the "Comprehensive ICF Core Set for 
Multiple Sclerosis" were confirmed by the participants, 49 categories were not 
named. Eight additional ICF categories which are currently not included in the "Com-
prehensive ICF Core Set for MS" were seen as important factors in the treatment of 
MS patients by more than 75 percent of the participating physicians.  
Conclusion: The validity of the "Comprehensive ICF Core Set for Multiple Sclerosis" 
was largely affirmed by the participating physicians. However, several additional 
categories were named whose inclusion in the "Comprehensive ICF Core Set for 
Multiple Sclerosis" need to be investigated further. 
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1 Introduction 
1.1 Multiple sclerosis 
Multiple sclerosis (MS) is a chronic inflammatory, demyelinating disease of the 
central nervous system (CNS) that can result in problems of functioning and health. It 
is one of the most common neurological diseases of the white population in the 
northern hemisphere and Australia. Worldwide around 2.5 million people are affected 
by MS (American National MS society, 2007), whereas the prevalence rates feature 
regional differences, for example in Germany the prevalence rate is about 149 per 
100000 habitants (Gleixner et al., 2007), while MS is rarely found in Black Africa. The 
prevalence of blacks in South Africa is about 0.22 per 100000 (Bhigjee et al., 2007). 
Generally, there are only few cases of MS near the equator, but the prevalence rate 
increases with the geographical equatorial distance (Kesselring, 2005). The age of 
onset of MS is between 20 and 40 years, but there are also cases where MS was 
diagnosed in childhood (Ferreira et al., 2008) or in advanced years (Azzimondi et al., 
1994). Women are more frequently affected by MS than men, the female to male 
ratio is about 3:2 (Gleixner et al., 2007). 
The aetiology of MS is not yet cleared finally but generally a combination of a 
multifactorial autoimmune process, genetic factors and additionally, environmental 
conditions seem to be involved in the genesis of this disease. There is a familiar 
increased risk to contract MS, for monozygotic twins it is 250 times higher than in the 
normal population, for siblings 30 times higher, whereas there is no higher risk for 
adopted or in law family members (Ebers et al., 1995; Ebers et al., 2000). A lot of 
different genes seem to play an important role for the risk to get MS as well as for the 
course of the disease, for example the human leukocyte antigen HLA-DR2 (Fazekas 
et al., 2001; Oksenberg et al., 2001; Barcellos et al., 2002). Also environmental 
conditions like climate related factors or virus infections are discussed to influence 
the genesis and course of MS (Gale et al., 1995; Ascherio et al., 2001; Nielsen et al., 
2007).  
MS is characterized by the chronic inflammation, the demyelination of the white as 
well as the grey matter of the CNS with multiple lesions, gliosis and the damage of 
axons. The mechanisms underlying these processes are multifactorial. Inflammation 
7 
cells, especially blood brain barrier penetrating t-lymphocytes (CD8+, and CD4+ T-
cells, macrophages), the destruction of oligodendrocytes as well as metabolic 
dysfunctions within the axons seem to be very important for the pathogenesis 
(Geurts et al., 2003; Neumann et al., 2003). The MS typical plaques which arise by 
reason of inflammation, demyelination and gliosis are located preferentially 
periventricular (lateral ventricle, at the ground of the fourth ventricle), in the 
cerebellum, brain stem, optic nerve and spinal cord (particular in the pyramidal tract, 
funiculus posterior) (Delank, 2006; Gleixner et al., 2007). As a result of the 
inflammatory demyelination and the axonal loss the transfer of the nerve impulses is 
disturbed which leads to diverse neurological deficits (Brück et al., 2005). 
The diagnosis of MS is a clinical one based on a detailed anamnesis, an extensive 
neurological examination and supplementary paraclinical tests like the Magnetic 
Resonance Imaging (MRI), the cerebrospinal fluid puncture and evoked potentials. 
According to the McDonald diagnostic criteria MS can be diagnosed if a 
dissemination of lesions in space and time can be demonstrated, either clinically on 
the basis of attacks or by using MRI (McDonald et al., 2001; Polman et al., 2005; 
Inglese et al., 2006). 
Typical symptoms at the beginning of MS are sensory deficits, paresis and visual 
dysfunctions. Sensory deficits often appear as paraesthesias or as a reduced 
sensation of vibrations at the distal legs. A characteristic sign of a feasible MS is the 
Lhermitte-sign (Lhermitte et al., 1924). Flexing the neck results in an electrical shock 
felt along the vertebral column and into the legs. Another typical but rare symptom is 
the so called "Oppenheim-hand" which can lead to a total unusable hand due to a 
plaque in the funiculus posterior (Kesselring & Beer, 2005). Motor deficits 
characteristically arise as paraparesis, paralysis of one leg or hemiparesis. Another 
highly prevalent symptom in the MS population is spasticity which is significantly 
associated with a reduced level of functional independence (Barnes et al., 2003). 
Furthermore muscle reflexes can be increased or understated and reflex zones can 
be broadened. The most important sign of a destruction of the pyramidal tract is the 
positive Babinski reflex in MS patients, which normally is negative from the age of 
one. Ataxia, dysmetria, dysdiadochokinesia, kinetic tremor and dysarthria allude to 
an affection of the cerebellum. Visual deficits can impress as an optic neuritis as a 
result of plaques in the optic nerve with a decrease of the vision up to blindness, as 
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eye movement dysfunctions with ghost images, as deviation nystagmus or as 
internuclear ophthalmoplegia (Kesselring & Beer, 2005; Gleixner et al., 2007). During 
the course of the disease MS patients experience a lot of further problems like 
sexual, bladder and / or bowel dysfunctions which influence quality of life (Nortvedt et 
al., 2007). Bladder dysfunctions include for example incontinence, dysuria and 
urinary retention, bowel dysfunctions mainly manifest in obstipation and sexual 
dysfunctions affect for example the loss of erection in men and anorgasmia in women 
(Tepavcevic et al., 2008). Other common symptoms of MS patients are related to 
cognitive and affective dysfunctions like problems in memory, problem solving, 
attention control or information processing speed (Kesselring & Beer, 2005; Jonsson 
et al., 2006). With a prevalence rate of about 50 percent depression is also a 
widespread problem of MS patients (Sadovnick et al., 1996; Bamer et al., 2008). 
Strongly associated with depressive symptoms is disabling fatigue, which is seen as 
the worst or one of the worst symptoms by the majority of MS patients (Fisk et al., 
1994; Chwastiak et al., 2005; Hadjimichael et al., 2008). Another characteristic and 
prevalent symptom is pain, more than 60 percent of MS patients are afflicted with 
chronic or acute pain syndromes (Stenager et al., 1991; Beiske et al., 2004). 
Because MS can affect almost every part of the CNS MS patients can feature an 
immense variability of symptoms which can change, increase or decrease in the 
course of the disease.  
Based on the clinical course MS can be classified in different types (Lublin et al., 
1996):  
• Relapsing-remitting (RR) MS is characterised by disease relapses and the 
following complete or partially remission. During the relapses new symptoms can 
appear or old ones could reappear or become worse. There is no disease 
progression in the time between the relapses. About 85% of MS patients are 
diagnosed with RRMS. 
• Primary progressive (PP) MS is defined as a continuous progression from the 
onset of the disease without remissions or intense relapses. Nevertheless there 
can be occasional plateaus or little improvements. It is a rare form of MS which 
affects approximately 10 percent of the patients. 
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• Secondary-progressive (SP) MS is characterized by the progression of the 
disease between the relapses. This type of MS evolves from the RRMS after 10 
to 20 years. 
• The progressive relapsing (PR) MS shows a continuous progression from the 
onset of the disease with clear acute relapses with or without recovery. Between 
the relapses the disease proceeds.  
The therapy of MS contains different components, the treatment of acute relapses, 
the prevention of relapses, the impairment impeding, the improvement of damaged 
parts of the CNS and of course the symptomatic treatment. According to the current 
treatment guidelines of the German Society of Neurology (Deutsche Gesellschaft für 
Neurologie (DGN), 2008) intravenous high-dosed methylprednisolone is used to treat 
acute relapses. To influence the course of the disease that means to reduce the 
frequency of relapses and stop the progression of disability the cytokines IFNß-1b 
(Betaferon®) and IFNß-1a (Avonex®, Rebif®) (Paty et al., 1993; Jacobs et al., 1995; 
Jacobs et al., 1996; PRISMS, 1998), the synthetic produced oligopeptide 
Glatirameracetate (Copaxone®) (Comi et al., 2001) and the humanised antibody 
Natalizumab (Tysabri®) (Polman et al., 2006) are approved. If these basis therapy 
possibilities fail it is also possible to treat RRMS with the reserve compound 
Azathioprin (e.g. Imurek®) (Goodin et al., 2002) and PR- or SPMS with Mitoxantrone 
(Ralenova®) (Hartung et al., 2002). Besides immunmodulating drugs the 
symptomatic therapy plays a decisive role within the multimodal therapy concept of 
MS. The symptomatic therapy includes not only the medication based treatment but 
also multidisciplinary rehabilitation procedures like physiotherapy, occupational 
therapy, speech therapy, psychological and social support as well as a 
comprehensive medical care including physicians of different disciplines (e.g. 
neurologists, urologists or ophthalmologists) and nursing staff (Deutsche Multiple 
Sklerose Gesellschaft (DMSG), 2004; Deutsche Gesellschaft für Neurologie (DGN), 
2008). Essential intervention goals are the elimination or reduction of symptoms to 
improve the functional ability, to avoid impairment of daily activities as well as of 
participation of occupational and social life, to improve independence and quality of 
life of MS patients. Therefore, the therapy of MS patients poses a great challenge 
and demands a close collaboration of a multimodal team (Stevenson & Playford, 
2007). 
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1.2 International Classification of Functioning, Disability and Health 
A comprehensive, efficient treatment for patients requires an interdisciplinary 
collaboration between the involved health professionals and other relevant instances. 
To assure the most efficient collaboration a common language for describing health 
and health-related states which can be used and understood by all parties is needed. 
The International Classification of Functioning, Disability and Health (ICF) provides 
such an unified and standard language (WHO, 2001). Since its approval in May 2001 
by the fifty-fourth World Health Assembly (WHA), which is a member of the World 
Health Organization (WHO) family of International Classification, all member states of 
the WHO are urged to implement the ICF in clinical practice. The ICF establishes an 
universal and generally accepted language for the description of health conditions 
and health-related states and a globally agreed-upon framework for all health 
professionals as well as researchers, policy makers and the public (WHO, 2001).  
The ICF is based on an integrative and functional model of health that provides a 
holistic, multidimensional and interdisciplinary understanding of health and health-
related states. It is divided into two parts: Functioning and Disability and Contextual 
Factors. According to the ICF Functioning and Disability refer to the ICF components 
Body Functions, Body Structures and Activities & Participation in life situations. Body 
Functions are defined as physiological and psychological functions of the body 
system whereas Body Structures contain the anatomical structures of the body like 
organs, limbs and their components. The component Activities & Participation 
includes all domains which are associated with the aspects of functioning from 
individual and societal perspective. Activity means the execution of a task of action 
by an individual and participation the involvement in life situations. The components 
of the part Functioning and Disability can be used to describe problems of patients 
like impairments of Body Functions and Body Structures, limitations of Activities and 
restrictions of Participation as well as to describe non-problematic aspects of health 
and health-related states (WHO, 2001). In this context Functioning characterizes the 
positive aspects and Disability the negative aspects of the interaction between an 
individual with a health condition and its contextual factors (WHO, 2001). The part 
Contextual Factors includes the components Environmental Factors and Personal 
Factors (WHO, 2001) (figure1, 2).  
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Health condition 
(disorder or disease) 
Body Functions 
and Structures Activities Participation 
Enviromental 
Factors 
Personal 
Factors 
 
Figure 1: Structure of the International Classification of Functioning, Disability and Health  
 
Environmental Factors can have an impact on all components of Functioning and 
Disability and include the physical, social and attitudinal environment of a person, 
which can be facilitating or hindering for the individual. Personal Factors that contain 
gender, race, age, lifestyle, habits, coping styles, social background etc. are not 
classified in the ICF so far.  
The construction of the ICF is hierarchical. Within each component there is a list of 
so-called ICF categories which are the units of the classification (WHO, 2001). ICF 
categories are part of chapters which constitute the first level of precision. The 
categories are denoted by unique alphanumeric codes composed by a letter that 
refers to the components of the classification (b: Body Functions; s: Body Structures; 
d: Activities & Participation; e: Environmental Factors) and followed by a numeric 
code starting with the chapter number (one digit), followed by the second level (two 
digits) and the third and fourth level (one digit each) (figure 2). An example from the 
component Body Functions is presented below:  
component: b - Body function 
chapter (1st level): b2 - Sensory functions and pain  
second level: b280 - Sensation of pain 
third level: b2801 - Pain in body part 
fourth level: b28015 - Pain in lower limb 
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Within each component the categories are arranged in a stem / branch / leaf scheme. 
Consequently a higher-level (more detailed) category shares the lower level category 
of which it is member. Therefore, when using a higher level category it is possible to 
apply the lower-level category but not vice versa. 
 
ICF
Functioning and Disability Contextual factors
Body Functions
and Structures
Activities and 
Participation
Environmental
Factors
Personal 
Factors
b1-b8 s1-s8 d1-d9 e1-e5
b110-
b899
s110-
s899
d110-
d999
e110-
e599
b1100-
b7809
s1100-
s8309
d1550-
d9309
e1100-
e5959
b11420-
b54509
s11000-
s76009
Not classified
Classification
Parts
Components
Chapters/      
1st level
2nd level
3rd level
4th level
Categories
 
Figure 2: Structure of the International Classification of Functioning, Disability and Health; 
hierarchical arrangement. 
 
Altogether, the ICF contains more than 1400 categories each allotted into the 
components named above except of the Personal Factors which are not yet 
classified. To facilitate the application of the ICF in clinical practice, the ICF Core 
Sets project was initiated in 2001 by the ICF Research Branch of the WHO 
Collaboration Center of the Family of International Classifications (DIMDI) at the 
Ludwig-Maximilians-Universität in Munich, Germany, together with the Classification, 
Terminology and Standards Team (CTS Team) at WHO and an increasing number of 
partner organizations (Stucki, 2004). The aim of this study is to select sets of ICF 
categories out of the whole classification that include the typical spectrum of 
problems in functioning in patients with a specific condition (Stucki, 2004; Cieza et 
al., 2004). These so called ICF Core Sets can serve as Comprehensive ICF Core 
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Sets which contain enough categories for multiprofessional, comprehensive 
assessments (Stucki, 2004; Cieza et al., 2004) or as Brief ICF Core Sets which are 
characterized by a minimal standard for the reporting of functioning and health for 
clinical studies and encounters. They should include as many categories as 
necessary for describing problems in functioning of patients with a specific condition 
adequately but as few as possible to remain practical. Up to now 17 ICF Core Sets 
for chronic conditions have been developed, for example ICF Core Sets for 
rheumatoid arthritis, stroke, depression, chronic widespread pain and low back pain 
(Cieza et al., 2004). The aim of the ICF Core Sets is to establish a fundament for the 
development of assessment instruments to appraise the severity of a disease, the 
course of the disease as well as the effectiveness of interventions. It provides a 
common language to facilitate communication between different health professionals 
as well as between health professionals, patients, their families and family 
caregivers. Furthermore it should be used in research to improve understanding of 
functioning, disability and health with the aim to minimize disability among people 
with a disease and to enhance quality of life (Stucki, 2004; Kesselring et al., 2008).  
The ICF Core Sets for MS have been developed to establish useful standards for 
clinical practice and research (Kesselring et al., 2008). The development of the ICF 
Core Sets for MS comprises three phases: the so-called Preparatory Phase, Phase I 
and Phase II (Kesselring et al., 2008) (figure 3). 
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Figure 3: Development of ICF Core Sets for MS: phases of the project  
 
Within the Preparatory Phase four so-called preparatory studies were conducted to 
address adequately different perspectives. A systematic literature review was 
performed (1) to identify parameters and outcomes reported in studies involving 
patients with MS and published within the years 2002 to 2006 and (2) to identify and 
quantify the concepts contained in those parameters and outcomes using the ICF as 
a reference. Within the qualitative study six focus groups with individuals afflicted 
with MS were performed at the Kempfenhausen Centre for Treatment of Multiple 
Sclerosis (Germany) to identify aspects of functioning and health, which are 
important to the individuals and to list those aspects using the ICF as a reference 
(Coenen et al., submitted). An internet based expert survey was performed to gather 
the opinion of an international pool of 173 experts of different health professions 
(physicians, nurses, physiotherapists, occupational therapists, (neuro-)psychologists, 
speech and language therapists and social workers) regarding the most relevant and 
typical areas to be considered in individuals with MS). A cross-sectional multicentre 
study with 205 patients was performed at centres in Switzerland and Germany 
(Valens Rehabilitation Centre, Switzerland; Rehabilitation Center Quellenhof Bad 
Wildbad, Germany; University Hospital Zurich, Switzerland; Swiss Multiple Sclerosis 
Society, Switzerland) to describe functioning and health of individuals with MS and to 
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identify the most common problems using the classification system of the ICF (Holper 
et al., 2009). 
The results of these preparatory studies were presented at the ICF Core Set 
Consensus Conference for MS in May 2008 in Valens, where 21 experts in the field 
of MS (physicians, physiotherapists, social workers, psychologists, occupational 
therapists, speech and language therapists, nurses and a member of the MS Society 
of India) from 16 different countries (Argentina, Australia, Belgium, Canada, Estonia, 
Germany, India, New Zealand, Saudi Arabia, Slovenia, Spain, Sweden, Switzerland, 
Thailand, USA, UK) approved the first version of the ICF Core Sets for MS (Phase I). 
The Comprehensive ICF Core Set for MS includes 138 ICF categories covering the 
typical spectrum of problems in functioning of patients with MS. It includes 40 Body 
Functions, 7 Body Structures, 53 Activities & Participations and 38 Environmental 
Factors (Appendix 1). Based on the Comprehensive Core Set the candidate ICF 
categories of the Brief Core Set were defined (Appendix 2). 
According to the phases of the project the worldwide validation of the ICF Core Sets 
for MS using a number of approaches to validate their content and feasibility is 
necessary (Phase II). The validation of the Brief ICF Core Set for MS will be 
performed by further studies using several statistical analysis. The aim of the 
validation of the Comprehensive ICF Core Set for MS is (1) to confirm the ICF 
categories of the first version of the Comprehensive ICF Core Set, (2) to identify 
included ICF categories which might be not relevant and (3) to discover additional 
ICF categories which are not yet contained in the Comprehensive ICF Core Set for 
MS. One aspect within the validation process is the validation from the user 
perspective for which the Comprehensive ICF Core Set has been developed in the 
first place. Since the preparatory studies and the consensus process did not explicitly 
address the interventions applied by health professionals it is necessary to evaluate 
whether their perspective is sufficiently represented in the Comprehensive ICF Core 
Set for MS. Therefore it should be explored whether the categories included in the 
Comprehensive ICF Core Set cover the patients’ problems addressed by the specific 
interventions of health professionals. Moreover, the validation from the perspective of 
health professionals will contribute the worldwide acceptance and credibility of the 
Comprehensive ICF Core Set for MS. One group of health professionals involved in 
the interdisciplinary treatment and rehabilitation are physicians. 
16 
2 Objective 
The objective of this study was to validate the Comprehensive ICF Core Set for MS 
from the perspective of physicians. The specific aims were (1) to identify MS patients’ 
problems, resources and aspects of environment treated by physicians and (2) to 
analyse whether these issues are represented by the current version of the 
Comprehensive ICF Core Set for MS. 
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3 Methods 
3.1 Design 
A three-round electronic survey was used based on the Delphi technique. The Delphi 
technique is a special kind of a written survey to structure a group communication 
process with the aim to gain consensus from a panel of individuals, who have 
knowledge of the topic being investigated. These informed persons are commonly 
titled "experts" (Linstone et al., 1975; Hasson et al., 2000; Bortz & Döring, 2006). The 
name of this method refers to the Greek oracle, which should have given outstanding 
wise advices (Bortz & Döring, 2006). The Delphi process is a multistage process 
consisting of a series of structured questionnaires whereas each questionnaire is 
built up on the results of the previous one (Hasson et al., 2000). Traditionally, the 
initial questionnaire is an open-ended questionnaire to collect qualitative comments 
of the participants (Hasson et al., 2000; Hsu et al., 2007). These answers were 
analysed and reported to the participants in the second questionnaire. The results of 
the second round are the basis for the third questionnaire again (Hasson et al., 2000; 
Hsu et al., 2007). The third questionnaire includes statistical information about the 
distribution of the group’s response as well as the individual previous response, so 
each participant has the opportunity to revise or specify his/her answer (Jones & 
Hunter, 1995; Hasson et al., 2000; Hsu et al., 2007). 
According to Häder (2000) there are special criteria which characterize the Delphi 
technique:  
• application of a formalized questionnaire 
• survey of experts 
• anonymity of responses 
• identification of a statistical result of the group 
• information about the result is given to the participants 
• repetition of the survey 
Because of the anonymity of the participants’ responses which distinguishes the 
Delphi technique from other consensus methods the dominance of single individuals 
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who might influence the whole group can be avoided. Furthermore, it is a cost 
efficient method because a large group of experts without geographical limitations 
can participate by using e-mail (Jones & Hunter, 1995; Häder, 2000). Today the 
Delphi technique is used in different areas, for example in the development of 
sciences and technique, telecommunication, in the field of education, tourism, 
general economic applications, politics and the health care sector (Häder, 2000). 
 
3.2  Recruitment of participants 
The sample was selected using a purposive sampling approach. Purposive sampling 
is based on the assumptions that a researcher’s knowledge about the population can 
be used to handpick the cases to be included in the sample (Polit & Hungler, 1997). 
At the beginning of this study national and international associations of physicians as 
well as universities, hospitals, rehabilitation centres and former cooperation partners 
of the ICF Research Branch in Munich were contacted by e-mail with the request to 
participate in this study or to name physicians who are experienced in the treatment 
of MS patients. In addition, literature search and personal recommendations were 
used to identify experts. To assure that the participants of the study are "qualified 
individuals" concerning MS treatment, the initial letter notes that participants should 
be "physicians experienced in the treatment of MS".  
Within the first e-mail contact the physicians were invited to participate in the study 
"Validation of the Comprehensive ICF Core Set for MS from the perspective of 
physicians". A detailed description of the study, its background and goals were given 
and the task they have to perform as well as the timeline was explained (Appendix 
3). 
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3.3  Material and data collection 
The three-round Delphi exercise was accomplished by electronic-mail, started at the 
end of September 2008 and ended at the end of January 2009. In every round the 
participants had to return the filled in questionnaires within two weeks. Reminders 
were sent 3 days before deadline and 3, 8 and 14 days after deadline.   
The Delphi process with the verbatim questions of the study "Validation of ICF Core 
Set for MS from the perspective of physicians" is demonstrated in figure 4. 
 
 
Figure 4: Description of the Delphi exercise 
Question: 
What are MS patients` problems and 
resources as well as aspects of 
environment treated by physicians? 
• Linking of answers to ICF 
• Feedback of ICF categories 
(code, title, description of 
content) 
Question: 
Do you agree that this ICF category 
represents MS patients' problems, 
resources or aspects of environment 
treated by physicians? 
• Calculation of  frequencies 
• Feedback of individual and 
group answers 
Question: 
Taking into account the answer of the 
group and your individual answer in the 
second round, do you agree that this ICF 
category represents MS patients' prob-
lems, resources or aspects of environment 
treated by physicians? 
Round 1 
Round 3 
Round 2 
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3.3.1 Delphi round 1 
In the first Delphi round an open-ended questionnaire (figure 5) with the request to 
list all MS patients’ problems and resources as well as aspects of environment 
treated by physicians and an information letter with introductions how to fill in the 
questionnaire was sent to the MS experts who agreed to participate. 
Additionally, the questionnaire included questions about personal data of the 
participants. They should name their age, gender, the country they come from, their 
specialties / certifications, their current professional activity and the number of years 
of their professional experience as well as the years of their practical experience with 
patients with MS. They were asked to rate their experience in the treatment of 
patients with MS (1=low to 5=excellent).  
 
 
Figure 5: Questionnaire round I 
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Preparation of the data of the first Delphi round 
The answers of the first Delphi round were linked to ICF categories based on 
established linking rules (Cieza et al., 2002; Cieza et al., 2005) by two trained 
doctoral students.  
According to these linking rules each answer of the first round was linked to the most 
precise category of the ICF. If a statement applied to more than one category 
multiple ICF categories were linked. By using the abbreviation "pf" all statements 
related to Personal Factors could be classified. Answers that were not yet covered in 
the ICF assigned "nc". Statements which deal with a diagnosis or a health condition 
were allotted to "hc" (health condition). All "pf’s”, "hc’s” and "nc’s” were mentioned 
separately in the second questionnaire. If a statement was to general to classify it 
exactly in the ICF an "nd" (not definable) was assigned with the consequence that it 
did not appear in the second round. Table 1 shows an example of the linking 
procedure. 
 
 
Answer of participant 
 
 
 
Linked ICF 
category linker A 
 
Linked ICF 
category linker B 
 
Agreed on ICF 
category 
 
Spasticity b735 b735 b735 
Depression hc hc hc 
Sexual and sphincter 
disturbances b640, b620 b640, b525 b640, b525 
Carer burden e340 nc e340 
 
Table 1: Example of the linking procedure 
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To assure the quality of the linking process two procedures were established; namely 
multiple coding and peer review:  
(1) Multiple coding: each doctoral student had linked the answers of eight 
participants (132 statements). Afterwards the results were compared, discussed and 
a consensus was reached. In the case of disagreement a third opinion of another 
trained health professional (psychologist) was obtained.  
(2) Peer review: The answers of the first 33 questionnaires (585 statements) were 
linked independently by the two trained doctoral students without reaching a 
consensus. 
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3.3.2 Delphi round 2 
In the second Delphi round the linked categories of the first round were reported back 
to the participants who responded the first questionnaire. The second questionnaire 
included the ICF code, the title and the description of all linked ICF categories as well 
as all responses which were categorized as pf, hc and nc, respectively (figure 6). The 
participants were asked whether they agree that this ICF category represents MS 
patients’ problems, resources or aspects of environment treated by physicians.  
 
 
Figure 6: Questionnaire round 2 
 
Preparation of the data of the second round 
All answers of the second round were collected. The percentage of the agreement 
that an ICF category represents MS patients’ problems, resources, aspects of 
environment, personal factors, health conditions or not classified categories was 
calculated. The results and the individual answers were listed in the third 
questionnaire (figure 7). 
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3.3.3 Delphi round 3 
The third questionnaire included the ICF code, the title and the description of the ICF 
categories as in the second questionnaire and additionally a column with the 
identification numbers of all participants who agreed that this ICF category 
represents MS patients’ problems, resources or aspects of environment treated by 
physicians and a column with the percentage of agreement (figure 7). The 
questionnaire of the third round was sent to the participants who responded the 
questionnaire of the second round. Taking into account the answer of the group and 
their individual answer of the second round the participants should review his / her 
answer of the second round and answer the same question as in round two again. 
 
 
Figure 7: Questionnaire round 3 
 
Preparation of the data of the third round 
The identified ICF categories were compared to the categories of the Comprehensive 
ICF Core Set for MS. 
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3.4 Data analysis 
Descriptive statistics were applied to characterize the sample and frequencies of 
responses using SPSS 17.0 for Windows. Based on the answers of the participants 
of the third round the level of agreement that the corresponding ICF category 
represents MS patients’ problems, resources, aspects of environment, personal 
factors or health conditions treated by physicians was calculated. To check 
differences in age, professional and practical experience regarding the WHO regions 
nonparametric analysis (Kruskal-Wallis-test, p<0.05, Appendix 4) were performed 
using SPSS. To describe the agreement between the two doctoral students who 
performed the peer review of the linking process Kappa statistics with 95% 
bootstrapped confidence intervals (95% CI) were used. Values of Kappa range from 
0 to 1. A value of 1 indicates perfect agreement, a value of 0 indicates no agreement 
(Cohen, 1960; Vierkant, 2009). Kappa statistics were performed by using SAS 9.1. 
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4 Results 
4.1 Participants 
To get in contact with potential participants 211 MS and neurology associations and 
326 individual experts of all WHO regions were contacted. The number of contacts 
as well as the respective number of physicians who agreed to participate in the 
Delphi exercise is shown in Table 2.  
 
 
Way of contact 
 
 
Contacts 
n 
Physicians agreed to 
participate 
n 
Physicians 
participated in the 
first round 
n 
MS / neurology 
associations 211 16 15 
Expert pool of 
collaborating partners 105 37 31 
Internet search 141 12 8 
Personal 
recommendations 80 34 30 
Total 537 99 84 
 
Table 2: Results of the recruitment of participants 
 
A total of 99 physicians from 36 countries agreed to participate in the Delphi 
exercise, finally 84 MS experts (response rate 85 %) send back the filled in 
questionnaire of the first round. Table 3 shows the number of participants of the 
different rounds with respect to the WHO world regions. 
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WHO Region Participants n              
  Round 1 Round 2 Round 3 
European Region 54 52 50 
South-East Asia Region 6 4 4 
Western Pacific Region 6 5 5 
Region of the Americas 10 10 10 
African Region 3 3 3 
Eastern Mediterranean Region 5 5 4 
Total 84 79 76 
 
Table 3: Number of participants with respect to the WHO world regions 
 
In detail the participants of the first round came from the following countries: 
(1) Europe (64.3%): Austria (2 physicians), Azerbaijan (1), Belarus (1), Belgium (3), 
Bosnia & Herzegovina (1), Croatia (1), Germany (9), Greece (1), Hungary (2), 
Italy (5), Lithuania (2), Netherlands (4), Poland (1), Romania (3), Slovenia (3), 
Spain (5), Sweden (2), Switzerland (2), Turkey (2), United Kingdom (4).  
(2) South-East Asia Region (7.1%): India (4), Sri Lanka (1), Thailand (1).  
(3) Western Pacific Region (7.1%): Australia (2), Malaysia (1), Mongolia (2), New 
Zealand (1). 
(4) American Region (11.9%): Brazil (1), Canada (2), El Salvador (1), Mexico (1), 
United States of America (5).  
(5) Eastern Mediterranean Region (6.0%): Morocco (2), United Arabian Emirates 
(3). 
(6) African Region (3.6%): South Africa (1), Ghana (2).  
 
The demographic and professional data of the 84 physicians who completed the first 
round is shown in Table 4. 
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WHO Region Gender % Female 
Age  
Median 
(Range) 
Professional 
experience 
in years,  
Median 
(Range) 
Experience 
in treatment 
of patients 
with MS in 
years,  
Median 
(Range) 
Self-Rating 
of Expertise 
regarding 
MS*,  
Median 
(Range) 
European Region 44.4 44.0 (24-71) 18.0 (3-40) 13.0 (3-40) 4.0 (3-5) 
South-East Asia 
Region 33.3 47.0 (37-53) 18.5 (10-25) 11.5 (7-22) 4.0 (3-4) 
Western Pacific 
Region 66.7 44.0 (31-67) 13.0 (5-43) 7.5 (3-30) 4.0 (4-5) 
Region of the 
Americas 30.0 52.0 (46-72) 24.5 (15-46) 16.5 (12-36) 5.0 (4-5) 
African Region 33.3 37.0 (32-57) 10.0 (5-28) 8.0 (2-18) 3.0 (3-4) 
Eastern Mediterranean 
Region 80.0 45.0 (39-53) 20.0 (11-28) 10.0 (8-20) 4.0 (4-5) 
Total 45.2 46.0 (24-72) 18.0 (3-46) 13.0 (2-40) 4.0 (3-5) 
 
Table 4: Demographic and professional data of the participants, *1=low,  5=excellent  
 
The nonparametric analysis with the Kruskal-Wallis Test (p<0.05) showed that there 
were no significant differences regarding age, professional and practical experience 
between the participants of the six WHO world regions  (Appendix 4). 
Most participants were specialists in neurology but also physicians who are 
specialized in physical and rehabilitation medicine, in urology, psychiatry and 
neuroimmunology took part in this study.  
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The current professional activity of the participating MS experts ranges from acute 
clinics to rehabilitation centres and universities. Table 5 shows the current 
professional activities of the participants, whereas multiple answers were permitted.  
 
WHO Region 
Acute clinic 
n 
 
 
University / 
university 
hospital 
n 
Inpatient 
rehabilitation 
centre 
n 
Outpatient 
rehabilitation 
centre 
n 
others 
n 
 
 
European Region 27 19 16 7 5 
South-East Asia 
Region 3 5 1 1 0 
Western Pacific 
Region 3 1 1 0 2 
Region of the 
Americas 2 6 1 1 1 
African Region 2 1 0 0 2 
Eastern Mediterranean 
Region 
2 2 2 1 2 
Total  39 34 21 10 12 
 
Table 5: Current professional activity of the participants of round 1 
 
The second questionnaire was sent to all participants of the first round and was 
answered by 79 out of 84 physicians (94%) and 76 out of 79 physicians (96.2%) 
participated in round 3. Comparing the number of the experts who agreed to 
participate and the number of the participants of the third round a response rate of 
76.7 percent (76 out of 99) was achieved. 
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4.2 Results of the linking procedure 
In the first round 1735 statements out of 1443 answers of the participants were 
retrieved. One thousand four hundred fifty-two of them could be linked to a specific 
ICF category, 15 statements assigned pf, 64 were allotted to hc, 44 were not 
classified in the ICF and assigned nc and 160 statements were assigned nd.  
Totally, 166 different ICF categories (77 Body Functions, 53 Activities & Participation, 
34 Environmental Factors, 2 Body Structures) were linked to the statements of the 
participants and reported in the second questionnaire. Of the ICF component Body 
Functions 36 categories were linked on the second level, 34 on the third level and 7 
on the fourth level of the classification. Twenty-nine second level and 24 third level 
categories of the component Activities & Participation, 20 second level and 14 third 
level categories of the component Environmental Factors and one second level and 
one third level category of the component Body Structures were linked. The 
statements which were related to Personal Factors could be summarised to 6 pf’s, 64 
answers that characterized a health condition were abstracted to 10 hc’s and 44 
statements which were not classified in the ICF were combined in 8 nc’s. 
The Kappa statistics for the linking process was 0.82 with a 95 percent bootstrapped 
confidence interval from 0.79 to 0.86. 
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4.3 Results of the Delphi exercise 
Totally, 89 ICF categories of the Comprehensive ICF Core Set for MS were 
confirmed by the participating physicians either at the same or at a different level of 
classification, the remaining 49 ICF categories of the Comprehensive ICF Core Set 
were not confirmed. Furthermore 8 categories were named by more than 75 percent 
of the participants which are not yet included in the Comprehensive ICF Core Set for 
MS. A summary of the frequencies of the confirmed and additional ICF categories 
that were identified in the Delphi exercise for the Validation of the Comprehensive 
ICF Core Set for MS is shown in table 6.  
 
  Body 
Functions 
Body 
Structures 
Activities & 
Partici-
pation 
Environ-
mental 
Factors 
Total 
Number of categories 
identified  77 2 53 34 166 
n (%) of confirmed 
categories of the ICF Core 
Set at the same level of 
classification 
25 (32.5%) 1 (50.0%) 27 (50.9%) 23 (67.6%) 76 (46.4%) 
n (%) of confirmed 
categories of the ICF Core 
Set at a different level of 
classification 
35 (45.5%) 1 (50.0%) 24 (45.3%) 9 (26.5%) 69 (41.6%) 
n (%) of additional 
categories not included in 
Core Set with agreement 
<75% 
9 (11.7%) 0 2 (3.8%) 2 (5.9%) 13 (7.8%) 
n (%) of additional 
categories not included in 
Core Set with agreement 
≥75% 
8 (10.4%) 0 0 0 8 (4.8%) 
n (%) of not confirmed 
categories of the ICF Core 
Set 
7 (17.5%) 5 (71.4%) 22 (41.5%) 15 (39.5%) 49 (35.5%) 
 
Table 6: Representation of ICF categories identified in the Delphi exercise for MS: summary of 
results 
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4.3.1 Body Functions 
Table 7 shows the results of the component Body Functions of the Delphi exercise in 
comparison to the Comprehensive ICF Core Set for MS. 
Confirmed categories: Twenty-five categories of the Comprehensive ICF Core Set 
for MS were confirmed by the participants of the Delphi exercise at the same level of 
classification. With an agreement between 62.2 percent and 98.7 percent (mean 
88.8%) the participants held that these categories represent MS patients’ problems 
treated by physicians (21 second level categories, 4 third level categories).  
Thirty-five of the identified ICF categories were included in the ICF Core Set but at a 
different level of classification (6 fourth level categories, 26 third level categories, 3 
second level categories). The participants named for example the ICF categories 
b6202-Urinary continence, b6200-Urination and b6201-Frequency of urination, which 
confirm the corresponding second level category b620-Urination functions of the 
Comprehensive ICF Core Set for MS.  
Additional categories: Seventeen linked ICF categories were not included in the 
Comprehensive ICF Core Set for MS, not even on a different level of classification; 
eight of them reached an agreement of more than 75 percent. These additional 
categories are b215-Function of structures adjoining the eye, b240-Sensations 
associated with hearing and vestibular function, b435-Immunological system 
functions, b840-Sensation related to the skin, b1600-Pace of thought, b2401-
Dizziness, b6700-Discomfort associated with sexual intercourse and b43501-Non-
specific immune response. 
Not confirmed categories: The Comprehensive ICF Core Set for MS includes 
seven ICF categories which were not confirmed by the participants of the validation 
phase even not at a different level of classification. These categories are b114-
Orientation functions, b156-Perceptual functions, b235-Vestibular functions, b260-
Propioceptive functions, b310-Voice function, b5104-Salivation and b750-Motor 
reflex functions. 
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ICF Code ICF Category Title Round 3 n=76 
2nd level 3rd level 4th level   % agreement 
  b1101  Continuity of consciousness  71.2 
b114   Orientation functions   
b126   Temperament and personality functions   
  b1263  Psychic stability  94.6 
  b1265  Optimism 70.3 
b130   Energy and drive functions 82.2 
  b1300  Energy level    
  b1301  Motivation    
  b1308  Energy and drive functions, other specified (fatigue) 98.6 
b134   Sleep functions 79.7 
b140   Attention functions 79.5 
b144   Memory functions 87.8 
  b1440  Short-term memory  74.3 
b152   Emotional functions 90.5 
  b1522  Range of emotion  78.7 
b156   Perceptual functions   
   b1600 Pace of thought  83.8 
b164   Higher-level cognitive functions  88.0 
  b1641  Organization and planning  85.3 
b210   Seeing functions 90.7 
 b215  Functions of structures adjoining the eye 81.3 
b230   Hearing functions 62.7 
b235   Vestibular functions   
 b240  Sensations associated with hearing and vestibular function 98.6 
   b2401 Dizziness  98.7 
b250   Taste function 42.7 
b255   Smell function 32.0 
b260   Proprioceptive function   
b265   Touch function 89.3 
b270   Sensory functions related to temperature and other stimuli 93.3 
  b2700  Sensitivity to temperature  93.3 
  b2702  Sensitivity to pressure  83.8 
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ICF Code ICF Category Title Round 3 n=76 
2nd level 3rd level 4th level   % agreement 
b280   Sensation of pain 98.7 
  b2800  Generalized pain  97.3 
   b28010 Pain in head and neck  93.3 
   b28012 Pain in stomach or abdomen 58.7 
   b28013 Pain in back 90.5 
   b28014 Pain in upper limb 96.0 
   b28015 Pain in lower limb 97.3 
   b28016 Pain in joints 86.7 
b310   Voice function   
b320   Articulation functions 85.3 
b330   Fluency and rhythm of speech functions 82.2 
 b435  Immunological system functions 86.7 
   Non-specific immune response  b43501 76.0 
b440   Respiration functions 62.7 
b445   Respiratory muscle functions 69.3 
b455   Exercise tolerance functions   
  b4552  Fatiguability  98.7 
  b5101  Biting 41.3 
  b5102  Chewing  40.5 
  b5104  Salivation    
  b5105  Swallowing  90.7 
b525   Defecation functions 97.3 
  b5252  Frequency of defecation  94.6 
  b5253  Faecal continence 98.7 
b550    Thermoregulatory functions 58.7 
  b5500  Body temperature  62.2 
  b5508  Thermoregulatory functions, other specified (Sensitivity to heat)   
  b5508  Thermoregulatory functions, other specified (Sensitivity to cold)   
b620   Urination functions 96.0 
  b6200  Urination  95.9 
  b6201  Frequency of urination  97.3 
  b6202  Urinary continence  100.0 
b640   Sexual functions 95.9 
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ICF Code ICF Category Title Round 3 n=76 
2nd level 3rd level 4th level   % agreement 
  b6400  Functions of sexual arousal phase  82.4 
  b6403  Functions of sexual resolution phase  60.3 
b660   Procreation functions 68.9 
   b6700 Discomfort associated with sexual intercourse  94.7 
b710   Mobility of joint functions 82.7 
b730   Muscle power functions 89.3 
  b7303  Power of muscles in lower half of the body  88.0 
  b7305  Power of muscles of the trunk  80.0 
b735   Muscle tone functions 96.0 
  b7350  Tone of isolated muscles and muscle groups  93.2 
  b7353  Tone of muscles of lower half of body  93.3 
  b7354  Tone of muscles of all limbs  93.2 
  b7355  Tone of muscles of trunk  94.4 
  b7356  Tone of all muscles of the body  93.1 
b740   Muscle endurance functions 82.7 
  b7401  Endurance of muscle groups  77.0 
b750   Motor reflex functions   
b760   Control of voluntary movement functions 95.9 
b765   Involuntary movement functions 93.2 
  b7650  Involuntary contractions of muscles    
 b7651  Tremor 97.3 
b770   Gait pattern functions 94.6 
b780   Sensation related to muscles and movement functions   
  b7800  Sensation of muscle stiffness  98.6 
  b7801  Sensation of muscle spasm  100.0 
b810   Protective functions of the skin 62.4 
  b840   Sensation related to the skin 97.3 
 
Table 7: ICF component Body Functions: ICF categories included in the Comprehensive ICF 
Core Set for MS (bold font), ICF categories linked to participants’ responses and included in 
the Comprehensive ICF Core Set at a different level of classification (normal font), additional 
categories not included in the Comprehensive ICF Core Set with an agreement < 75% (cursive 
font) and with an agreement >75% (cursive, underlined) and ICF categories included in the ICF 
Core Set but not confirmed by the participants (bold, cursive font). Percentage of participants 
who considered the respective ICF category as relevant in the third round. 
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4.3.2 Body Structures 
Table 8 shows the results of the component Body Structures of the Delphi exercise in 
comparison to the Comprehensive ICF Core Set for MS. 
Confirmed categories: Two of the ICF categories of the Comprehensive ICF Core 
Set for MS were confirmed by the MS experts of the Delphi exercise. The second 
level category s810-Structure of areas of the skin is included on the same level in the 
Comprehensive ICF Core Set for MS. The second confirmed category is s1106-
Structure of cranial nerves which represents the second level category s110 of the 
Comprehensive ICF Core Set. 
Additional categories: The participants named no additional ICF category of the 
component Body Structures. 
Not confirmed categories: Five ICF categories of the Comprehensive ICF Core Set 
were not confirmed by the participants. 
 
ICF Code ICF Category Title Round 3              n=76 
2nd level 3rd level   % agreement 
s110  Structure of brain   
  s1106 Structure of cranial nerves  69.9 
s120  Spinal cord and related structures   
s610  Structure of urinary system   
s730  Structure of upper extremity   
s750  Structure of lower extremity   
s760  Structure of trunk   
s810   Structure of areas of skin 63.0 
 
Table 8: ICF component Body Structures: ICF categories included in the Comprehensive ICF 
Core Set for MS (bold font), ICF categories linked to participants’ responses and included in 
the Comprehensive ICF Core Set at a different level of classification (normal font) and ICF 
categories included in the ICF Core Set but not confirmed by the participants (bold, cursive 
font). Percentage of participants who considered the respective ICF category as relevant in the 
third round. 
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4.3.3 Activities & Participation 
Table 9 shows the results of the component Activities and Participation of the Delphi 
exercise in comparison to the Comprehensive ICF Core Set for MS. 
Confirmed categories: Twenty-seven ICF categories of the Comprehensive ICF 
Core Set for MS were confirmed by the participants at the same level of classification 
(50.9%). Twenty-four of the identified categories (45.3%) are included in the 
Comprehensive ICF Core Set but at a different level of classification. For example the 
third level category d4154-Maintaining a standing position confirms the second level 
category d451-Maintaining a body position of the Comprehensive ICF Core Set for 
MS. 
Additional categories: Two ICF categories were linked which are not included in the 
Comprehensive ICF Core Set for MS. These are d335-Producing nonverbal 
messages and d855-Non-remunerative employment. 
Not confirmed categories: Twenty-two ICF categories of the chapter Activities & 
Participation which are included in the Comprehensive ICF Core Set for MS were not 
confirmed in this study. These categories derived from all chapters of the component 
Activities and Participation. 
 
ICF Code ICF Category Title Round 3              n=76 
2nd level 3rd level   % agreement 
d110  Watching   56.8 
d155  Acquiring skills   
d160  Focusing attention   
d163  Thinking    
d166  Reading 62.2 
d170  Writing   
d175  Solving problems    
d177  Making decisions   
d210  Undertaking a single task   
d220  Undertaking multiple tasks   
d230  Carrying out daily routine 83.8 
  d2303 Managing one's own activity level 78.4 
d240  Handling stress and other psychological demands   
38 
ICF Code ICF Category Title Round 3              n=76 
2nd level 3rd level   % agreement 
  d2401 Handling stress 83.8 
d330  Speaking 71.6 
d335  Producing nonverbal messages  56.8 
d350  Conversation   
d360  Using communication devices and techniques   
d410  Changing basic body position 82.2 
  d4103 Sitting  83.6 
  d4104 Standing 85.1 
d415  Maintaining a body position   
  d4154 Maintaining a standing position  94.5 
d420  Transferring oneself 85.1 
d430  Lifting and carrying objects      
d440  Fine hand use 83.8 
d445  Hand and arm use 83.8 
d450  Walking 90.5 
  d4500 Walking short distances  89.2 
  d4501 Walking long distances  82.4 
d455  Moving around      
  d4551 Climbing 79.5 
  d4552 Running  74.3 
d460  Moving around in different locations 79.7 
  d4600 Moving around within the home 86.7 
  d4601 Moving around within buildings other than home 77.3 
  d4602 Moving around outside the home and other buildings 78.7 
d465  Moving around using equipment 80.0 
d470  Using transportation  77.3 
d475  Driving 82.7 
  d4751 Driving motorized vehicles 84.9 
d510  Washing oneself 86.7 
  d5101 Washing whole body  85.3 
d520  Caring for body parts   
d530  Toileting  82.4 
  d5301 Regulating defecation  81.3 
d540  Dressing    84.0 
d550  Eating 84.0 
d560  Drinking 82.7 
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ICF Code ICF Category Title Round 3              n=76 
2nd level 3rd level   % agreement 
d570  Looking after one’s health 86.7 
  d5701 Managing diet and fitness  82.7 
  d5702 Maintaining one's health  89.3 
d620  Acquisition of goods and services    
  d6200 Shopping  53.3 
d630  Preparing meals 61.3 
d640  Doing housework    62.7 
  d6402 Cleaning living area  60.8 
d650  Caring for household objects    
d660  Assisting others   
d710  Basic interpersonal interactions   
d720  Complex interpersonal interactions   
d750  Informal social relationships   
d760  Family relationships 75.7 
d770  Intimate relationships 74.7 
  d7702 Sexual relationships  74.7 
d825  Vocational training   
d830  Higher education   
d845  Acquiring, keeping and terminating a job 76.0 
  d8451 Maintaining a job 74.7 
d850  Remunerative employment 62.7 
d855  Non-remunerative employment 56.0 
d860  Basic economic transactions    
d870  Economic self-sufficiency   
d910  Community life   
d920  Recreation and leisure 64.0 
  d9201 Sports 53.3 
  d9204 Hobbies 47.3 
d930  Religion and spirituality 22.7 
  d9300 Organized religion 17.3 
 
Table 9: : ICF component Activities and Participation: ICF categories included in the 
Comprehensive ICF Core Set for MS (bold font), ICF categories linked to participants’ 
responses and included in the Comprehensive ICF Core Set at a different level of classification 
(normal font), additional categories not included in the Comprehensive ICF Core Set with an 
agreement < 75% (cursive font) and with an agreement >75% (cursive, underlined) and ICF 
categories included in the ICF Core Set but not confirmed by the participants (bold, cursive 
font). Percentage of participants who considered the respective ICF category as relevant in the 
third round. 
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4.3.4 Environmental Factors 
Table 10 shows the results of the component Environmental Factors of the Delphi 
exercise in comparison to the Comprehensive ICF Core Set for MS. 
Confirmed categories: Twenty-three ICF categories of the Comprehensive ICF 
Core Set for MS were confirmed by the participants of the Delphi exercise at the 
same level of classification (70.6%). Nine categories which were named by the 
participants are included in the Comprehensive ICF Core Set for MS at a lower level 
of classification (26.5%), for example e1150-General products and technology for 
personal use in daily living and e1151-Assistive products and technology for personal 
use in daily living confirm the second level category e115-Products and technology 
for personal use in daily living of the ICF Core Set for MS.  
Additional categories: The linked ICF categories e2600-Indoor air quality and e510-
Services, systems and policies for the production of consumer goods are the only 
two categories that are not included in the Comprehensive ICF Core Set for MS but 
the agreement that these categories represent MS patient’s aspects of environment 
treated by physicians was lower than 75 percent. 
Not confirmed categories: Further 15 ICF categories are included in the 
Comprehensive ICF Core Set for MS which were not confirmed by the participants of 
the Delphi exercise. These categories derived from all chapters of the component 
Environmental Factors. 
 
ICF Code ICF Category Title Round 3              n=76 
2nd level 3rd level    % agreement 
  e1101 Drugs  90.7 
  e1108 Products or substances for personal consumption, other 
specified 
84.0 
e115  Products and technology for personal use in daily living  78.7 
  e1150 General products and technology for personal use in daily 
living 
53.3 
  e1151 Assistive products and technology for personal use in 
daily living 
89.3 
e120  Products and technology for personal indoor and outdoor 
mobility and transportation  
89.2 
  e1201 Assistive products and technology for personal indoor and 
outdoor mobility and transportation  
90.7 
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ICF Code ICF Category Title Round 3              n=76 
2nd level 3rd level    % agreement 
e125  Products and technology for communication   
e135  Products and technology for employment 68.0 
e150  Design, construction and building products and 
technology of buildings for public use 
37.3 
e155  Design, construction and building products and 
technology of buildings for private use 
36.0 
e165  Assets 24.0 
  e2250 Temperature  42.7 
  e2251 Humidity  22.7 
  e2253 Precipitation   
  e2600 Indoor air quality  21.3 
e310  Immediate family 58.7 
e315  Extended family 37.3 
e320  friends   
e325  Acquaintances, peers, colleagues, neighbours and 
community members 
44.0 
e330  People in positions of authority   
e340  Personal care providers and personal assistants 90.7 
e355  Health professionals 94.7 
e360  Other professionals 66.7 
e410  Individual attitudes of immediate family members   
e415  Individual attitudes of extended family members   
e420  Individual attitudes of friends   
e425  Individual attitudes of acquaintances, peers, colleagues, 
neighbours and community members 
  
e430  Individual attitudes of people in positions of authority   
e440  Individual attitudes of personal care providers and 
personal assistants 
  
e450  Individual attitudes of health professionals   
e460  Societal attitudes   
e510  Services, systems and policies for the production of 
consumer goods 
41.1 
e515  Architecture and construction services, systems and 
policies 
 
e525  Housing services, systems and policies 44.6 
e540  Transportation services, systems and policies 51.4 
  e5400 Transportation services 53.3 
e550  Legal services, systems and policies   
e555  Associations and organizational services, systems and 
policies 
58.1 
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ICF Code ICF Category Title Round 3              n=76 
2nd level 3rd level    % agreement 
  e5550 Associations and organizational services 58.1 
e570  Social security services, systems and policies 74.7 
  e5700 Social security services 78.7 
e575  General social support services, systems and policies 64.0 
  e5750 General social support services 66.7 
e580  Health services, systems and policies 94.7 
  e5800 Health services 96.0 
e585  Education and training services, systems and policies   
e590  Labour and employment services, systems and policies 54.7 
  e5950 Political services 30.7 
 
Table 10: ICF component Environmental Factors: ICF categories included in the 
Comprehensive ICF Core Set for MS (bold font), ICF categories linked to participants’ 
responses and included in the Comprehensive ICF Core Set at a different level of classification 
(normal font), additional categories not included in the Comprehensive ICF Core Set with an 
agreement < 75% (cursive font) and with an agreement >75% (cursive, underlined) and ICF 
categories included in the ICF Core Set but not confirmed by the participants (bold, cursive 
font). Percentage of participants who considered the respective ICF category as relevant in the 
third round. 
43 
4.3.5 Personal Factors 
Table 11 shows the results of the component Personal Factors of the Delphi 
exercise. At least 90 percent of the physicians considered each of the six Personal 
Factors as relevant. 
 
Answer Round 3              n=76 
  % agreement 
    
Coping 91.9 
    
Dependency from others / devices 91.9 
    
Loss of control 90.7 
    
Self-esteem 91.8 
    
Uncertainness about future 92.0 
    
Unrealistic therapeutic expectations 96.0 
 
Table 11: Responses that were linked to the ICF component Personal Factors. Percentage of 
participants who considered the respective response as relevant 
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4.3.6 Health Conditions 
Table 12 shows the health conditions which were named in the Delphi exercise. 
 
Answer Round 3              n=76 
  % agreement 
    
Depression 100.0 
    
Dementia 97.3 
    
Trigeminal neuralgia 100.0 
    
Epilepsy 97.3 
    
Oscillopsia 97.3 
    
Aspiration pneumonia 98.6 
    
Ileus and subileus 90.7 
    
Restless legs 94.5 
    
Psychotic disorders 94.6 
    
Osteoporosis 95.9 
 
Table 12: Responses that characterize a health condition. Percentage of participants who 
considered the respective response as relevant in the third round. 
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4.3.7 Not Classified 
Table 13 shows the main statements which are not classified in the ICF. 
 
Answer Round 3              n=76 
  % agreement 
    
Diagnostic and follow-up procedures (diagnosis, MS relapses, prognosis, 
disease course) 
100.0 
    
Use of adaptive devices 97.3 
    
Change of roles /role models 78.7 
    
Falls 98.7 
    
Information about MS 98.7 
    
Pregnancy planning 97.3 
    
Professional future 96.0 
    
Travelling with medications 94.6 
 
Table 13: Responses that could not be linked to a specific ICF category since the linking unit is 
not covered by the ICF. Percentage of participants who considered the respective response as 
relevant in the third round. 
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5 Discussion 
5.1 Discussion of the results 
The results of this study largely affirm the validity of the Comprehensive ICF Core Set 
for MS from the perspective of physicians. Sixty five percent of the ICF categories of 
the current version of the Comprehensive ICF Core Set were confirmed by the 
participants. Almost each of the linked categories of the ICF components Body 
Structures, Activities and Participation and Environmental Factors is included in the 
Comprehensive ICF Core Set for MS either at the same or at a different level of 
classification. Seventeen linked categories of the component Body Functions are not 
included in the Comprehensive ICF Core Set for MS, whereas only eight of these 
categories reached an agreement of at least 75 percent. Furthermore several 
Personal Factors as well as other aspects that are not covered by the ICF 
classification but treated by physicians were identified.  
 
5.1.1 Body Functions 
The Comprehensive ICF Core Set for MS includes 40 ICF categories of the 
component Body Functions, the majority of them were confirmed by the participants 
of the Delphi exercise either at the same or at a different level of classification. For 
example, the category b1308-Energy and drive functions, other specified (fatigue) 
was confirmed by 98.6 percent of the participants. However, the corresponding 
categories b1300-Energy level and b1301-Motivation were not named by the 
physicians. These categories represent the second level category b130-Energy and 
drive functions which is not included in the Comprehensive ICF Core Set but was 
additionally mentioned by the participating physicians. “Fatigue” is described as one 
of the main problems of MS patients with prevalence rates of more than 50 percent, 
the majority of MS patients even describes it as the worst or one of the worst 
symptom with a significant effect on the mental health and general health status (Fisk 
et al., 1994; Hadjimichael et al., 2008). Hence it should be reconsidered whether it is 
reasonable to include all three categories b1300, b1301 and b1308 in the 
Comprehensive ICF Core Set for MS or only the category b1308-Fatigue. 
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The category b780-Sensation related to muscles and movement functions was not 
confirmed on the second level but on the more detailed third level of the 
classification. Almost all participants agreed that the categories b7800-Sensation of 
muscle stiffness and b7801-Sensation of muscle spasm represent relevant problems 
of MS patients’ treated by physicians. So the importance of these ICF categories was 
supported from the clinical perspective. Forty-seven percent of the MS patients of the 
study of Barnes et al. (2003) and 84 percent of the interviewed patients in the study 
of Rizzo et al. (2004) reported clinical significant spasticity. Instead of the second 
level category b780-Sensation related to muscles and movement functions the 
inclusion of the more detailed categories b7800 and b7801 seems to be appropriate 
and should be discussed during the revision process. 
Additionally, the participants named 17 ICF categories which are not yet contained in 
the Comprehensive ICF Core Set for MS; eight thereof had an agreement of more 
than 75 percent. Before discussing these categories in detail one has to mention that 
some of these categories are related to side effects of medication used to treat MS.  
The question whether ICF categories concerning side effects of medication should be 
included in the Comprehensive ICF Core Set for MS has to be considered carefully. 
With the advent of new medications, new side effects may appear. On the one hand, 
one has to keep in mind that the ICF Core Set describes functioning and disability of 
MS patients independent of the treatment. On the other hand, the intake of 
medication and the suffering of side effects belong to the reality of patients with MS. 
Perhaps one solution to this dilemma could be the development of treatment-specific 
ICF Core Sets.  
From the majority of the participants the categories b240-Sensations associated with 
hearing and vestibular function and b2401-Dizziness were seen as relevant problems 
of MS patients treated by physicians. The study of Beer and Kesselring as well as the 
study of Sundström demonstrated that eight percent of the MS patients are afflicted 
with vertigo as a defined onset attack symptom (Beer & Kesselring, 1988; Sundström 
et al., 2004). Frohmann and colleagues examined 1153 MS patients, 6.8 percent of 
them had experienced an episode of true vertigo at some time during their illness. 
Benign paroxysmal positioning vertigo (BPPV) was the most common cause of 
vertigo in this study followed by a new demyelinating plaque within the brainstem 
(Frohmann et al., 2000; Frohmann et al., 2003). When vertigo occurs on the basis of 
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inflammatory demyelination, the medial vestibular nucleus (MVN) and the root entry 
zone of cranial nerve VIII represent the most common neuroanatomical localizations 
(Francis et al., 1992; Gass et al., 1998; Thömke et al., 1999). On the assumption that 
an acute inflammatory demyelinating exacerbation constitutes the vertigo a treatment 
with corticosteroids and vestibular suppressants (e.g. diazepam, clonazepam) might 
be indicated. When the diagnosis of BPPV is established, particle repositioning 
manoeuvres are the treatment of choice and will lead to complete resolution of 
vertigo in most patients (Frohmann et al., 2003). Furthermore it should be considered 
that a number of drugs for the symptomatic treatment of MS patients can cause 
vertigo as advice effect, e.g. Gabapentin for the treatment of spasticity, Modafenilfor 
for the treatment of fatigue or Sildanefil for the treatment of sexual dysfunctions 
(Deutsche Multiple Sklerose Gesellschaft (DMSG), 2004). So it is up to the physician 
to detect the cause of the vertigo and choose the adequate treatment for the patient. 
That’s why the inclusion of at least the second level category b240-sensations 
associated with hearing and vestibular function into the Comprehensive ICF Core Set 
for MS in addition to the already existing category b230-Vestibular functions should 
be discussed. 
The category b840-Sensation related to the skin is another issue which was identified 
to be relevant in the treatment of MS patients by almost all participants and which is 
not included in the Comprehensive ICF Core Set for MS. The epidemiologic study of 
Beer and Kesselring already demonstrated that 41.3 percent of the MS patients are 
afflicted with paraesthesias at the onset of the disease (Beer & Kesselring, 1988). 
Also 40 percent of the MS patients analysed by Sander and Arts mentioned 
paraesthesia as a symptom (Sander & Arts, 1986). Paraesthesias can also appear 
as paroxysmal symptoms which last only some hours and end spontaneously as 
shown in the case report of Khan and Olek (1995). Paraesthesias are often 
associated with pain (Beiske et al., 2004) which is described as burning, itching, 
electric and formication (feeling as if ants were crawling across your skin) (Rae-Grant 
et al., 1999). In the study of Beiske and colleagues about 40 percent of the patients 
reported that these symptoms had important influence on daily activities, hence it is 
important to treat these sensations (Beiske et al., 2004). The current guidelines of the 
symptomatic treatment of MS that were approved by the German Multiple Sclerosis 
Society (DMSG) in 2004 recommend Amitriptyline, Carbamazepine, Gabapentin, 
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Lamotrigine or Morphine as possible medication of paraesthesias or dysaesthesias 
(DMSG, 2004). Another point that should be considered is the developing of 
paraesthesias or polyneuropathies as side effects of drugs that are used for the 
symptomatic treatment of MS, for example Aminopyridin for the treatment of fatigue 
or Isoniazid which is used to improve tremor (DMSG, 2004). It becomes apparent 
that physicians are often faced with problems which are mentioned in the ICF 
category b840-Sensation related to skin, so an inclusion of this category in the 
Comprehensive ICF Core Set for MS to complement the existing category s810-
Structure of areas of skin should be considered.  
Another ICF category considered to be relevant in the treatment of MS by the 
participating physicians is b6700-Discomfort associated with sexual intercourse. 
Neither this category nor the corresponding second level category b670-Sensation 
associated with genital and reproductive functions are contained in the 
Comprehensive ICF Core Set for MS. Sexual dysfunctions in general can arise at 
any time during the course of MS with a prevalence rate of about 50 to 90 percent 
(Zorzon et al., 1999). Schapiro (1998) maintains that more than 70 percent of all 
women with MS and 90 percent of all men with MS reported some change in their 
sexual life after the onset of the disease. To date, research on the sexuality of 
individuals with MS has focused primarily on factors that influence the physical 
aspects of sexuality, such as performance and arousal (Gagliardi, 2003). Women are 
mostly affected by impaired genital sensations, anorgasmia or hyporgasmia, reduced 
libido as well as decreased vaginal lubrication. Men often suffer from total or 
incomplete loss of erection, impotence or erectile dysfunction, ejaculatory and 
orgasmic dysfunctions and reduced libido (Zorzon et al., 1999). The study of 
Zivadinov and colleagues demonstrated that symptoms of sexual dysfunctions are 
associated with sphincter dysfunctions, bladder dysfunctions, fatigue, depression, 
anxiety and cognitive impairment (Zivadinov et al., 1999). In addition to these 
physical impairments emotional and psychological aspects like self-esteem, body 
image, relationships with others and self-identification are intertwined with sexuality 
(Richardson & Lazur, 1995) as well as demographic factors like present age and age 
at onset of symptoms, low educational level, unemployment and marriage (Zivadinov 
et al.,1999). It becomes obvious that a lot of different aspects influence sexuality of 
MS patients with great implications on the quality of life of these individuals. 
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However, the majority of sexual problems reported in literature are covered by the 
existing ICF Core Set category b640-sexual dysfunction, so the need for the inclusion 
of the category b6700-Discomfort associated with sexual intercourse is not proved 
sufficiently and should be discussed regarding the results of other validation studies. 
Nevertheless it is appropriate for physicians to address sexual function within the 
context of routine health assessment although they might feel uncomfortable or 
inadequately trained to discuss sexual issues with their patients (Schmidt et al., 
2005; Vermillion et al., 1997).  
Furthermore the ICF categories b435-Immunological system functions and b43501-
Non-specific immune responses were seen as relevant problems of MS patients‘ 
treated by physicians by the participants but are not included in the Comprehensive 
ICF Core Set for MS. These categories represent an important aspect especially from 
the perspective of physicians because several drugs of the basic therapy of MS 
affect immunosuppressive or immunomodulating. The consequence of the treatment 
with immunosuppressive drugs is the reduction of autoagressive immunocompetent 
cells as well as the reduction of normal or counter-regulatory immunocompetent cells. 
This could breed to an increased liability to infections. However, in clinical practice 
this is rarely a problem (Kesselring, 2005). In 1985 Sibley and colleagues already 
recognized that patients with MS are less susceptible for infections than healthy 
individuals, but MS exacerbations were related to infections (Sibley et al., 1985). This 
was proved by numerous studies. Rapp and colleagues found that 35 percent of MS 
patients experienced a relapse also had a bacterial infection (Rapp et al., 1995). 
Correale and colleagues reported that there was a significant association between 
systemic infections and risk of MS relapses, increased MRI activity, and T cells 
activation (Correale et al., 2006). Besides, many MS patients suffer from urinary tract 
dysfunctions that can lead to urinary tract infections. Metz and colleagues present 
three case studies from an MS clinic where recurrent urinary tract infections were 
associated with acute exacerbation and neurological progression refractory to 
intravenous steroid treatment (Metz et al., 1998). This demonstrates that 
immunological system functions play an important role in the daily life of MS patients 
either because of the influence of drugs or because of the risk of relapses related to 
infections. Therefore it should be discussed whether these ICF categories or at least 
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the second level category b435-Immunological system functions should be included 
in the Comprehensive ICF Core Set for MS. 
The category b1600-Pace of thought was also identified to be relevant in the 
treatment of MS patients. Currently, neither this ICF category nor the corresponding 
second level category b160-Thought function is included in the Comprehensive ICF 
Core Set for MS. Neuropsychological studies demonstrate that many MS patients 
show cognitive impairment with prominent involvement of memory, sustained 
attention and information processing speed (Bobholz & Rao, 2003; Amato et al., 
2006). In literature the prevalence rates of cognitive impairments in MS patients 
diversify between 43 and 65 percent (Medaer et al., 1984; Rao et al., 1984; Rao et 
al., 1991; McIntosh-Michaelis et al., 1991; Faiss et al., 2007). Further studies 
demonstrate that cognitive deficits correlate with brain lesion and brain atrophy (Rao 
et al., 1989; Rovaris et al., 1998), whereas the localization defines the cognitive 
impairment (Swirsky-Saretti et al., 1992; Rovaris et al., 2000). Furthermore cognitive 
dysfunction can have long-term effects on patients and their families (Kesselring & 
Beer, 2005). The study of Amato and colleagues demonstrated that MS patients 
suffer from cognitive impairment had to modify or discontinue their work activity, had 
limitations in social interactions and required assistance in their personal lives 
(Amato et al., 2001). Also an association of impaired cognition with anxiety, fatigue 
and depression could be proved (Arnett et al., 2001; Faiss et al., 2007; Simionit et al., 
2007) whereas no coherence between cognitive dysfunction and physical disability 
was found (Rao et al., 1991; Amato et al., 2006; Faiss et al., 2007). Cognitive 
impairment as well as the related depressive and anxiety symptoms result in a 
decreased quality of life (Cutajar et al., 2000; Benito-Leon et al., 2002). So it is 
necessary for the physician to recognise cognitive deficits as early as possible and to 
start the treatment to minimise these effects on the patients’ life. Currently non-
pharmacological measures like cognitive rehabilitation, occupational therapy and 
psychotherapy are focused on because only few effective pharmacological agents 
are approved as symptomatic therapy (Deutsche Multiple Sklerose Gesellschaft, 
2004; Krupp et al., 2004; Kesselring & Beer, 2005). Several cognitive impairments 
like memory and learning deficits, attention deficits and executive dysfunctions are 
already represented in the Comprehensive ICF Core Set for MS by the ICF 
categories b140-Attention function, b144-Memory functions and b164-Higher level 
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cognitive functions. Another relevant cognitive dysfunction that can be affected in MS 
patients but is not yet included in the Comprehensive ICF Core Set for MS is the 
information processing speed (Rao et al., 1989; Faiss et al., 2007). This affection 
could be covered by the suggested ICF category b1600-Pace of thought, so an 
inclusion of this category should be initiated to complete the mental functions’ ICF 
categories named above. 
The majority of the participants held that the ICF category b215-Function of 
structures adjoining the eye describes relevant problems of MS patients treated by 
physicians. One symptom which belongs to this category is nystagmus. Charcot 
already included this symptom in his classical symptom triad that comprises 
nystagmus, intention tremor and scanning or staccato speech. Nystagmus is found in 
more than the half of the MS patients, whereas various types can be distinguished 
(Kesselring, 2005). The most common type is the horizontal optokinetic nystagmus; 
57 percent of the examined MS patients in the study of Johnsen and colleagues 
featured this symptom (Johnsen et al., 1976). However, this kind of nystagmus 
should not be overestimated because it also can be found as a consequence of 
tiredness or missing cooperation (Kesselring, 2005). The acquired pendular 
nystagmus was diagnosed in four percent of the MS patients analysed by Aschoff 
and colleagues (1974). This study also demonstrated that patients with pendular 
nystagmus always suffered from severe cerebellar symptoms such as trunk ataxia, 
head tremor, intention tremor, or the cerebellar type of speech disturbance. 
Therefore, the cerebellar nuclei are obviously the structures the lesions of which may 
cause pendular nystagmus (Aschoff et al., 1974). Further types of nystagmus which 
can be found in patients with MS are spontaneous nystagmus, positional nystagmus 
(Johnsen et al., 1976), Downbeat nystagmus (Massucci & Kurtzke, 1988) or see-saw 
nystagmus (Sandramouli et al., 2005; Samkoff et al., 1994). To recognize nystagmus 
is more relevant for diagnosis than for therapy because a pharmacological treatment 
of nystagmus is difficult (Bandini et al., 2001). However, additional surgical 
approaches could improve the nystagmus (Jain et al., 2002). Since nystagmus is a 
classical, characteristic symptom of MS the inclusion of the ICF category b215-
Function of structures adjoining the eye into the Comprehensive ICF Core Set for MS 
should be considered, although the treatment is complicated. 
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Seven ICF categories of the Comprehensive ICF Core Set for MS were not confirmed 
by the participating physicians. These are b114-Orientation functions, b156-
Perceptual functions, b235-Vestibular functions, b260-Propioceptive functions, b310-
Voice function, b5104-Salivation and b750-Motor reflex functions. Perhaps these are 
usually treated by other health professionals but not by physicians. The categories 
b310-Voice function and b5104-Salivation describe typical work areas of speech 
therapists. The therapeutic aim of speech therapists is to correct voice dysfunctions, 
speech disorders, language disorders and dysphagia (Brauer & Tesak, 2003). Voice 
and speech dysfunctions as well as dysphagia are common problems of MS patients 
(de Pauw et al., 2002; Calcagno et al., 2002; Hartelius & Svensson, 1994). 
Therefore, it is important that these ICF categories are included in the 
Comprehensive ICF Core Set for MS although the participating physicians did not 
confirm these categories. The categories b750-Motor reflex functions, b235-
Vestibular functions, b156-Perceptual functions and b260-Proprioceptive functions 
represent work areas of physiotherapists and occupational therapists. The primary 
aims of physiotherapists are to restore and maintain function, activity and 
independence (MS Trust, 2006). They improve or maintain muscle activity, balance, 
mobility, posture and joint range (Stevenson & Playford, 2007) which are 
characteristic problems of MS patients. Occupational therapists enable people to 
achieve health, well-being, independence and life satisfaction through participation in 
occupation (MS Trust, 2006) by learning or re-learning ways in which activities can 
be performed, by adapting the activity or by modifying the environment (Stevenson & 
Playford, 2007).  
Since the treatment and rehabilitation of MS patients requires a multidisciplinary 
team it is necessary to include treatment goals of all engaged health professionals 
into the Comprehensive ICF Core Set for MS. So the results of further validation 
studies including different health professions must be compared to decide which of 
the categories of the Comprehensive ICF Core Set for MS describe the profile of MS 
patients comprehensively and therefore should be confirmed or not confirmed. 
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5.1.2 Body Structures 
Two ICF categories of the component Body Structures of the Comprehensive ICF 
Core Set for MS were confirmed by the participants. These are s810-Structure of 
areas of the skin and s1106-Structure of cranial nerves. The Comprehensive ICF 
Core Set for MS includes five further ICF categories which were not confirmed by the 
participants. That shows that the physicians participating in the Delphi exercise held 
that body structures are not the major problem they try to treat, perhaps because 
they can not influence for example the structure of the brain. Mainly they care about 
the implications because of changes for example in the structure of cranial nerves by 
treating the respective Body Functions, either with drugs, physical therapy or 
psychological counselling (Kesselring, 2005). Therefore the results of the other 
validation studies must be regarded and analysed to decide which Body Structures’ 
categories should be contained in the Comprehensive ICF Core Set for MS. 
 
5.1.3 Activities & Participation 
More than half of the ICF categories of the component Activities and Participation of 
the Comprehensive ICF Core Set for MS were confirmed by the participants of the 
Delphi exercise either at the same or at a different level of classification, especially 
various ICF categories of the chapters d2-General tasks and demands, d4-Mobility, 
d5-Self-care, d7-Interpersonal interactions and relationships and d8-Major life areas. 
Furthermore, there are several categories which are included in the Comprehensive 
ICF Core Set for MS which were not confirmed by the participating physicians. This 
might be traced back to the fact that these ICF categories describe typical work areas 
of other health professionals than physicians. For example the categories d520-
Caring for body parts and d650-Caring for household objects represent activities 
characteristically treated by occupational therapists (MS Trust, 2006). Since the care 
of MS patients requires a multi- and interdisciplinary team the results of the validation 
studies with other health professionals must be regarded to decide whether these 
ICF categories represent relevant problems of MS patients and therefore must be 
contained in the Comprehensive ICF Core Set for MS. 
 
55 
5.1.4 Environmental Factors 
The majority of the ICF categories of the component Environmental Factors was 
confirmed by the participants for example the categories e110-Drugs, e120-Products 
and technology for personal indoor and outdoor mobility and transportation, e340-
Support from personal care providers and personal assistants, e355-Support from 
health professionals or e580-Health services, systems and policies.  
Once again, the ICF categories that were not confirmed by the physicians might 
represent work areas of other health professionals like occupational therapists, 
physiotherapists or social workers. 
Peculiar is that not even one of the ICF categories of the chapter e4-Attitudes were 
confirmed by the participating physicians while at least one category of the other 
chapters of the Environmental Factors was named. Also the study of Khan and 
Pallant identified seven ICF categories of the chapter e4-Attitudes to be relevant in 
the treatment of MS patients (Khan & Pallant, 2007). One reason could be that 
physicians simply do not have enough time in their daily clinical routine to affect the 
attitudes of family members, friends or colleagues towards the disease and the 
patient. One way to influence attitudes and reduce prejudices might be an improved 
flow of information and education about the disease and its consequences. Another 
reason for not appearing of e4-categories might be a linking mistake influenced by 
the individual position of the linkers. To find out more about the importance of this 
chapter for MS patients the results of the different validation studies must be 
analysed. 
 
5.1.5 Personal Factors 
According to the ICF language a considerable number of the participants’ responses 
could be identified as Personal Factors. All identified Personal Factors of the Delphi 
exercise reached an agreement of more than 90 percent which demonstrate their 
importance for MS patients’ treatment that was already reported in the study of Khan 
and Pallant (2007). One considerable Personal Factor that was identified in this study 
and that is consistently pointed out in literature is "Coping". Individuals’ coping is 
defined as the result of a stress appraisal process and its purpose is to manage 
psychological stress (Lazarus, 2000). People with MS need to cope with 
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unpredictable worsening of health, changing social and intimate relationships and 
increasing support needs, which results in an increasing dependency from others. 
Dependency from others and / or devices was also seen as an important Personal 
Factor treated by physicians by the participants. The general well-being of MS 
patients depends upon how they adapt to these changing circumstances. The fact 
that things seem to be occurring that the individual’s can not control may lead to 
negative reactions. The feeling of loosing control that was also named by the 
participating physicians may lead to feel helpless and become depressed (McCabe 
et al., 2004). The association between the way of coping and depression, 
psychological factors and quality of life was demonstrated in several studies (Arnett 
et al., 2002; McCabe et al., 2004; Goretti et al., 2009). In a qualitative study 
Somerset and colleagues emphasize the aspects of life that contributed to the quality 
of the lives of people with MS (Somerset et al., 2002). Personal control as well as 
uncertainty about the course of the disease and the future, which was also 
emphasized as a Personal Factor by the participants of the validation study, emerged 
as important factors in terms of the quality of life of the interviewed MS patients. Also 
support can influence quality of life either in a positive or in a negative way. 
Inappropriate support can result in feelings of dependency and these were 
accompanied by loss of personal control. Furthermore this study pointed out that 
health and social care professionals were well placed to provide and coordinate 
effective support, and to recognise and ameliorate the damaging impact of 
dependency. On the other hand the health professionals were also seen as a source 
of frustration because they fall short of MS patients’ expectations. Also the majority of 
the participating physicians in this validation study had to face the problem of 
unrealistic therapeutic expectations. It becomes obvious that almost all physicians as 
well as other health professionals treating MS patients are confronted with the 
Personal Factors that were identified in the Delphi exercise because these Personal 
Factors are important aspects in the life of MS patients and they are not only 
interrelated among each other but also influence characteristic symptoms of MS 
patients. These findings stress the need to develop the component Personal Factors 
in future revisions of the ICF to get a comprehensive and complete description of 
relevant aspects influencing a patient’s functioning and health.  
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5.1.6 Health Conditions 
Ten health conditions related to MS were named by the participating physicians, 
Depression and Trigeminus neuralgia even with an agreement of 100 percent. This 
shows that diseases resulting from MS and associated with MS play an important 
role in the treatment of MS patients.  
 
5.1.7 Not Classified 
In the Delphi exercise several issues were identified that seem to be very important 
for physicians treating MS patients but are not covered by the ICF. "Diagnostic and 
follow-up procedures" were seen as a relevant issue as well as "information about 
MS". Previous studies have shown that patients with MS require a lot of information 
at time of receiving the diagnosis as well as in the course of the disease especially 
during acute exacerbations (Baker, 1998; Box et al., 2003). Lode and colleagues 
found that the quality of information given at the time of diagnosis is related to coping 
styles in patients with MS (Lode et al., 2007). Patients who were satisfied with the 
information employed more often actively coping than avoidance coping. However 
43.2 percent of the MS patients in this study were dissatisfied with the information by 
the time of diagnosis. Johnson suggests in his study that imparting a diagnosis of MS 
should be seen as the start of a transition that needs to be made explicit to the 
patient and closely linked to the provision of sources of information, advice and 
ongoing support as people learn to live with and manage the disease (Johnson, 
2003). But not only MS patients need information, all people with chronic conditions 
need support from providers in supply and engagement with information, in a way 
which gives legitimacy to the person's own self-care strategies and possible 
alternatives (Protheroe et al., 2008). So it is not amazing that the participants of the 
Delphi exercise held that diagnostic and follow-up procedures as well as well 
informed patients are necessary to care for their patients to recognize and treat 
problems or feasible relapses at an early stage. However one could say that these 
issues are covered by the environmental factor e580-health services, systems and 
policies but on the other hand it should be considered whether these terms are to 
important for all patients suffering from chronic diseases to disappear in this huge 
ICF category. 
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Strongly associated with "information about MS" is the statement "pregnancy 
planning". Since the age of onset of MS is between 20 and 40 years a lot of women 
in childbearing age are affected by this issue. So it is important that the physician 
informs and advices the patient about all topics related to pregnancy and MS and 
clarifies that pregnancy does not adversely affects the course of the disease and vice 
versa (Lee & O´Brian, 2008). The PRIMS study proved that pregnancy is probably 
neutral overall in terms of disease activity (Vukusic et al., 2004). An approximate 70 
percent reduction in relapse rate was seen in the third trimester of pregnancy, while 
there was a compensatory increase in the first postpartum trimester. Also the disease 
progression was not affected by pregnancy (Vukusic et al., 2004). Nevertheless the 
risks of drugs used for the treatment of MS in pregnancy must be considered. While 
Prednisolon and Azathioprine seem to be safe in pregnancy, Methotrexat as well as 
Interferone-ß should be stopped before conception (Lee & O`Brian, 2008). So 
physicians should support MS patients in pregnancy planning by giving information 
about the positive and negative impacts of pregnancy in MS. Since this issue affects 
all patients with chronic diseases the development of a category "pregnancy 
planning" in the ICF in addition to the category b660-Procreation functions should be 
aspired. 
Another issue that was identified is "falls". In the study of Nilsagard and colleagues 
63 percent of the analysed MS patients reported repetitive falls during the course of 
their disease whereas most falls occurred indoors during activities of daily life 
(Nilsagard et al., 2009). The odds of falling were increased by the use of walking 
aids, by disturbed proprioception and increased spasticity. So falls are consequences 
of various factors like disordered Body Functions and additional Environmental 
Factors, which are already covered by the ICF classification. 
The remaining four identified statements that were not classified in the ICF are 
"Professional future", "Use of adaptive devices", "Travelling with medications" and 
"Change of roles/role models". 
The identified term "Professional future" is associated with the ICF category d850-
Remunerative employment. The study of Gronning and colleagues showed that 
approximately 50 percent of MS patients are unemployed within ten years of disease 
onset (Gronning et al., 1990). Khan and colleagues reported that work-related 
problems were common in patients with MS and that there are still not enough 
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specific interventions to support vocation or to lessen the impact of unemployment 
(Khan et al., 2006). Besides occupation is often linked with high stress and high 
physical or mental work that can worsen the disease (Simmons et al., 2004). 
"Professional future" is highly connected with the term "uncertainness about future" 
which was already discussed in the chapter Personal Factors.  
"Travelling with medications" is another issue MS patients as well as all other 
individuals with acute or chronic diseases must mind. There are special regulations 
about medications in each country which have to be regarded. In general it is 
important to keep all medication and syringes in their original packaging. Often a 
medical certification of the physician that describes the imperative of using this 
medication and the accurate dosing is necessary (Auswärtiges Amt, 2009). Airlines 
and airports usually have strict rules about travelling with medications, so this should 
also be checked before travelling. Furthermore the storage and transport of the drugs 
must be considered, for example some drugs can only be out of the fridge for a 
certain length of time (MS Society, 2009). There are a lot of things that must be kept 
in mind when travelling with a chronic disease like MS and physicians can assist their 
patients in planning a travel. However, it is no term for the description of health and 
health-related states like it is provided by the ICF classification.  
The identified term "Use of adaptive devices" could be covered on closer examination 
by several ICF categories of the chapter 1-Products and technologies of the 
component Environmental Factors, so an additional inclusion of this term into the ICF 
seems not required.  
The last statement that is not classified in the ICF classification is "Change of role / 
role models". Obviously the role of MS patients as well as of their family members, 
friends and care givers change during the course of the disease. As the study of 
Gronning and colleagues showed many MS patients become unemployed during the 
course of their disease, so they do not earn their own money any more and are 
hooked on their spouses or social insurances (Gronning et al., 1990). Also the 
increasing disability leads to a larger dependence on family members or caregivers. 
So during the course of the disease the active autonomous individual could change 
to a needy constrained patient. However, also family members especially spouses 
experience a change of their role. They adopt more and more the role of a caregiver 
(Courts et al., 2005) with consequences in relationship satisfaction and quality of life. 
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The study of Patti and colleagues demonstrated that caregiving was associated with 
lower mental health, vitality and general health scores, compared to healthy subjects 
(Patti et al., 2007). Furthermore different health professionals like physicians, nurses, 
physiotherapists or occupational therapists play an increasing role in the daily life of 
MS patients caused by the incremental disability.  
In this validation study several statements emerged which are not yet covered by the 
ICF classification. Analysing the results of other validation studies the development of 
appropriate categories should be aspired. 
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5.2 Discussion of the methods 
The Delphi technique proved to be an appropriate method for this study. In this study 
response rates of 85 to 94 percent between the three rounds were achieved, in 
contrast to attrition rates of 50 percent or higher reported in the literature (Geschka 
1977, Race & Planek 1992). However, regarding the external validity and reliability of 
this study there are some limitations which should be mentioned. Since no database 
of the target population is available it was not possible to randomize the sample. That 
means although the sample of this study included 84 physicians from 36 countries it 
is not assured that it represents a representative sample of physicians who are 
experienced in the treatment of MS patients. However, qualitative research methods 
in general and the Delphi technique in particular are characterized by the 
impossibility of random sampling (Hasson et al., 2000; Williams & Webb, 1994).  
The majority of the participants come from the European Region. Therefore it could 
be possible that this influences the results. The reasons for the dominance of 
European participants might be a better e-mail access in Europe compared to South 
America or Africa. Also the prevalence rate of MS differ depending on the country 
(Gleixner et al., 2007; Bhigjee et al., 2007; Kesselring, 2005), so in Europe there are 
more physicians who are experienced in MS than in Africa. However, the results of 
the statistic tests show that there is no significant difference between the physicians 
of the different WHO World regions regarding age, professional and practical 
experience. Nevertheless, further validation studies should include physicians from 
countries not sufficiently represented in this study. 
The linking of the statements of the participants of the first Delphi round was 
performed by two trained medical doctoral students. Perhaps other health care 
professionals would have linked differently. On the other hand the linking agreement 
of the two students was calculated by using kappa statistics and proved to be 
satisfactory. 
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6 Conclusion 
The Comprehensive ICF Core Set for MS represents the typical spectrum of 
problems in functioning of patients with MS. For the validation of this ICF Core Set 
the physician’s perspective is extremely important because physicians deliver the 
diagnosis and accompany the patient in the treatment and course of the disease. The 
current version of the Comprehensive ICF Core Set for MS could be largely 
confirmed by the participating physicians. However, several additional ICF categories 
not included in the Comprehensive ICF Core Set for MS emerged and several ICF 
categories included in the Comprehensive ICF Core Set for MS were not confirmed 
by the participants. The findings of this study also stress the need to develop the 
component Personal factors. 
It is important to analyse and discuss the results of further finished or ongoing 
validation studies of the Comprehensive ICF Core Set for MS during the revision 
process with the aim of a potentially modified version of the Comprehensive ICF Core 
Set for MS which describes health and health-related states of MS patients as best 
as possible. 
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10 Appendix 
Appendix 1 Comprehensive ICF Core Set for Multiple Sclerosis 
 
Body Functions 
ICF Code ICF Category Title 
2nd level 3rd level  
b114   Orientation functions 
b126   Temperament and personality functions 
  b1300 Energy level  
  b1301 Motivation  
  b1308 Energy and drive functions, other specified (Fatique) 
b134   Sleep functions 
b140   Attention functions 
b144   Memory functions 
b152   Emotional functions 
b156   Perceptual functions 
b164   Higher-level cognitive functions  
b210   Seeing functions 
b235   Vestibular functions 
b260   Proprioceptive function 
b265   Touch function 
b270   Sensory functions related to temperature and other stimuli 
b280   Sensation of pain 
b310   Voice functions 
b320   Articulation functions 
b330   Fluency and rhythm of speech functions 
b445   Respiratory muscle functions 
b455   Exercise tolerance functions 
  b5104 Salivation  
  b5105 Swallowing  
b525   Defecation functions 
  b5500 Body temperature  
  b5508 Thermoregulatory functions, other specified (Sensitivity to heat) 
  b5508 Thermoregulatory functions, other specified (Sensitivity to cold) 
b620   Urination functions 
b640   Sexual functions 
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ICF Code ICF Category Title 
2nd level 3rd level  
b710   Mobility of joint functions 
b730   Muscle power functions 
b735   Muscle tone functions 
b740   Muscle endurance functions 
b750   Motor reflex functions 
b760   Control of voluntary movement functions 
  b7650 Involuntary contractions of muscles  
  b7651 Tremor  
b770   Gait pattern functions 
b780   Sensations related to muscles and movement functions 
 
 
Body Structures 
ICF Code ICF Category Title 
2nd level 3rd level  
s110   Structure of brain 
s120   Spinal cord and related structures 
s610   Structure of urinary system 
s730   Structure of upper extremity 
s750   Structure of lower extremity 
s760   Structure of trunk 
s810   Structure of areas of skin 
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Activities & Participation 
ICF Code ICF Category Title 
2nd level 3rd level  
d110   Watching   
d155   Acquiring skills 
d160   Focusing attention 
d163   Thinking  
d166   Reading 
d170   Writing 
d175   Solving problems  
d177   Making decisions 
d210   Undertaking a single task 
d220   Undertaking multiple tasks 
d230   Carrying out daily routine 
d240   Handling stress and other psychological demands 
d330   Speaking 
d350   Conversation 
d360   Using communication devices and techniques 
d410   Changing basic body position 
d415   Maintaining a body position 
d420   Transferring oneself 
d430   Lifting and carrying objects    
d440   Fine hand use 
d445   Hand and arm use 
d450   Walking    
d455   Moving around    
d460   Moving around in different locations 
d465   Moving around using equipment 
d470   Using transportation  
d475   Driving 
d510   Washing oneself 
d520   Caring for body parts 
d530   Toileting  
d540   Dressing    
d550   Eating 
d560   Drinking 
d570   Looking after one’s health 
d620   Acquisition of goods and services  
d630   Preparing meals 
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ICF Code ICF Category Title 
2nd level 3rd level  
d640   Doing housework    
d650   Caring for household objects  
d660   Assisting others 
d710   Basic interpersonal interactions 
d720   Complex interpersonal interactions 
d750   Informal social relationships 
d760   Family relationships 
d770   Intimate relationships 
d825   Vocational training 
d830   Higher education 
d845   Acquiring, keeping and terminating a job 
d850   Remunerative employment 
d860   Basic economic transactions  
d870   Economic self-sufficiency 
d910   Community life 
d920   Recreation and leisure 
d930   Religion and spirituality 
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Environmental Factors 
ICF Code ICF Category Title 
2nd level 3rd level  
  e1101 Drugs  
  e1108 Products or substances for personal consumption, other specified (Special formulations of food to maintain safety and nutrition) 
e115   Products and technology for personal use in daily living  
e120   Products and technology for personal indoor and outdoor mobility and transportation  
e125   Products and technology for communication 
e135   Products and technology for employment 
e150   Design, construction and building products and technology of buildings for public use 
e155   Design, construction and building products and technology of buildings for private use 
e165   Assets 
  e2250 Temperature  
  e2251 Humidity  
  e2253 Precipitation 
e310   Immediate family 
e315   Extended family 
e320   Friends 
e325   Acquaintances, peers, colleagues, neighbours and community members 
e330   People in positions of authority 
e340   Personal care providers and personal assistants 
e355   Health professionals 
e360   Other professionals 
e410   Individual attitudes of immediate family members 
e415   Individual attitudes of extended family members 
e420   Individual attitudes of friends 
e425   Individual attitudes of acquaintances, peers, colleagues, neighbours and community members 
e430   Individual attitudes of people in positions of authority 
e440   Individual attitudes of personal care providers and personal assistants 
e450   Individual attitudes of health professionals 
e460   Societal attitudes 
e515   Architecture and construction services, systems and policies 
e525   Housing services, systems and policies 
e540   Transportation services, systems and policies 
e550   Legal services, systems and policies 
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ICF Code ICF Category Title 
2nd level 3rd level  
e555   Associations and organizational services, systems and policies 
e570   Social security services, systems and policies 
e575   General social support services, systems and policies 
e580   Health services, systems and policies 
e585   Education and training services, systems and policies 
e590   Labour and employment services, systems and policies 
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Appendix 2 Brief ICF Core Set for Multiple Sclerosis – candidate 
categories 
 
Body Functions 
ICF Code ICF Category Title 
b130 Energy and drive functions 
b140 Attention functions 
b144 Memory functions 
b152 Emotional functions 
b164 Higher-level cognitive functions  
b210 Seeing functions 
b280 Sensation of pain 
b455 Exercise tolerance functions 
b620 Urination functions 
b640 Sexual functions 
b730 Muscle power functions 
b735 Muscle tone functions 
b760 Control of voluntary movement functions 
b770 Gait pattern functions 
 
Body Structures 
ICF Code ICF Category Title 
s110 Structure of brain 
s120 Spinal cord and related structures 
s610 Structure of urinary system 
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Activities & Participation 
ICF Code ICF Category Title 
d175 Solving problems  
d230 Carrying out daily routine 
d240 Handling stress and other psychological demands 
d450 Walking    
d455 Moving around    
d530 Toileting  
d570 Looking after one’s health 
d640 Doing housework    
d760 Family relationships 
d770 Intimate relationships 
d850 Remunerative employment 
d870 Economic self-sufficiency 
 
Environmental Factors 
ICF Code ICF Category Title 
e115 Products and technology for personal use in daily living  
e120 Products and technology for personal indoor and outdoor mobility and transportation  
e310 Immediate family 
e355 Health professionals 
e410 Individual attitudes of immediate family members 
e540 Transportation services, systems and policies 
e570 Social security services, systems and policies 
e580 Health services, systems and policies 
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Appendix 3 First e-mail  
 
WHO research project on Multiple Sclerosis and physicians 
Dear [xxx]/[member of xxx], 
 
In the context of a WHO international research project (please find a detailed description of 
our study in the attached files) we are currently searching for physicians with outstanding 
expertise in treatment of patients with Multiple Sclerosis (MS). 
 
We are just wondering whether any of your member(s) might be interested in participating in 
our international study, which is to validate the Comprehensive ICF Core Set for MS from 
the perspective of physicians. It would be a great support if you were able to name expert(s) 
in your association or country who are experienced in the treatment of MS patients. 
 
The International Classification of Functioning, Disability and Health (ICF) Research Branch 
is located at the Department of Physical Medicine and Rehabilitation at the Ludwig-
Maximilian University of Munich, Germany. Professor Gerold Stucki is the director of our 
department as well as of the ICF Research Branch. Briefly, our target is to implement the 
ICF, which was approved by the World Health Assembly in May 2001, in clinical practice. 
Recently, we have developed ICF Core Sets for sixteen diseases, including MS. 
 
To validate the Comprehensive ICF Core Set for MS we are going to evaluate whether all 
relevant interventions applied to patients with MS by physicians are included in the 
respective ICF Core Set. 
 
A Delphi exercise (via email) will be performed to gather the experts-opinion of health 
professionals worldwide. The participation of physicians will be one of the most important 
parts of this project. 
 
On behalf of Professor Stucki, we would like to thank you for your co-operation and 
collaboration in this vital WHO international research project.  
 
We look forward to hearing from you as soon as possible. 
 
Yours sincerely, 
 
Stephanie Berno, PhD student  Michaela Coenen, PhD, MPH 
 
____________________________________________________________ 
Please respond to: 
 
Stephanie Berno 
Institute for Health and Rehabilitation Sciences  
ICF Research Branch of WHO CC FIC (DIMDI)  
Ludwig-Maximilian University  
Marchioninistr. 17  
81377 Munich  
Germany 
Phone: +49 89 2180 227Fax: +49 89 2180 78230  
mailto:stephanie.berno@med.uni-muenchen.de 
www.icf-research-branch.org 
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Appendix 4 Kruskal-Wallis-Test 
 
Verarbeitete Fälle 
 Fälle 
 Eingeschlossen Ausgeschlossen Insgesamt 
 N Prozent N Prozent N Prozent 
Age  * WHO_region 84 100,0% 0 ,0% 84 100,0% 
prof_exp  * WHO_region 84 100,0% 0 ,0% 84 100,0% 
pract_exp  * WHO_region 84 100,0% 0 ,0% 84 100,0% 
 
 
Zusammenfassung von Fällen 
Gruppierter Median 
WHO_region Age prof_exp pract_exp 
European Region 44,2857 17,6000 13,0000 
South-East Asia Region 47,0000 18,5000 11,5000 
Western Pacific Region 44,0000 13,0000 7,3333 
Region of the Americas 52,0000 24,5000 16,6667 
African Region 37,0000 10,0000 8,0000 
Eastern Mediterranean 
Region 
45,0000 20,0000 12,6667 
Insgesamt 45,7778 18,3750 13,0000 
 
Ränge 
 WHO_region N Mittlerer Rang 
Age European Region 54 39,69 
South-East Asia Region 6 45,83 
Western Pacific Region 6 38,25 
Region of the Americas 10 63,55 
African Region 3 30,33 
Eastern Mediterranean Region 5 39,10 
Gesamt 84  
prof_
exp 
European Region 54 40,23 
South-East Asia Region 6 42,17 
89 
Western Pacific Region 6 35,83 
Region of the Americas 10 60,65 
African Region 3 30,00 
Eastern Mediterranean Region 5 46,60 
Gesamt 84  
pract
_exp 
European Region 54 42,34 
South-East Asia Region 6 40,83 
Western Pacific Region 6 23,33 
Region of the Americas 10 61,25 
African Region 3 27,17 
Eastern Mediterranean Region 5 40,90 
Gesamt 84  
 
 
 
 
 
Statistik für Testa,b 
 Age prof_exp pract_exp 
Chi-Quadrat 9,320 7,408 10,892 
df 5 5 5 
Asymptotische Signifikanz ,097 ,192 ,054 
a. Kruskal-Wallis-Test 
b. Gruppenvariable: WHO_region 
 
90 
Appendix 5 Results of the second Delphi round 
 
Body Functions 
ICF Code ICF Category Title Round 2              n=79 
2nd level 3rd level 4th level   % agreement 
  b1101  Continuity of consciousness  69.6 
b114   Orientation functions  
b126   Temperament and personality functions  
  b1263  Psychic stability  89.9 
  b1265  Optimism 67.1 
b130   Energy and drive functions 74.7 
  b1300  Energy level   
  b1301  Motivation   
  b1308 
 
Energy and drive functions, other specified 
(fatigue) 
98.7 
b134   Sleep functions 73.4 
b140   Attention functions 74.7 
b144   Memory functions 78.2 
  b1440  Short-term memory  70.9 
b152   Emotional functions 88.6 
  b1522  Range of emotion  75.6 
b156   Perceptual functions  
  b1600  Pace of thought  74.4 
b164   Higher-level cognitive functions  82.3 
  b1641  Organization and planning  78.2 
b210   Seeing functions 88.3 
b215   Functions of structures adjoining the eye 75.3 
b230   Hearing functions 64.1 
b235   Vestibular functions  
b240  
 
Sensations associated with hearing and 
vestibular function 
91.1 
  b2401  Dizziness  93.7 
b250   Taste function 51.9 
b255   Smell function 45.6 
b260   Proprioceptive function  
b265   Touch function 86.1 
b270  
 
Sensory functions related to temperature and 
other stimuli 
85.9 
  b2700  Sensitivity to temperature  88.5 
  b2702  Sensitivity to pressure  80.8 
b280   Sensation of pain 96.2 
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ICF Code ICF Category Title Round 2              n=79 
2nd level 3rd level 4th level   % agreement 
  b2800  Generalized pain  89.9 
   b28010 Pain in head and neck  87.3 
   b28012 Pain in stomach or abdomen 61.0 
   b28013 Pain in back 86.1 
   b28014 Pain in upper limb 88.6 
   b28015 Pain in lower limb 91.1 
   b28016 Pain in joints 79.7 
b310   Voice function  
b320   Articulation functions 78.5 
b330   Fluency and rhythm of speech functions 79.7 
b435   Immunological system functions 78.5 
   b43501 Non-specific immune response  73.1 
b440   Respiration functions 65.8 
b445   Respiratory muscle functions 69.2 
b455   Exercise tolerance functions  
  b4552  Fatiguability  96.2 
  b5101  Biting 57.1 
  b5102  Chewing  58.2 
  b5104  Salivation   
  b5105  Swallowing  85.9 
b525   Defecation functions 96.2 
  b5252  Frequency of defecation  89.9 
  b5253  Faecal continence 94.9 
b550    Thermoregulatory functions 65.8 
  b5500  Body temperature  68.4 
  b5508  Thermoregulatory functions, other specified 
(Sensitivity to heat) 
 
  b5508 
 
Thermoregulatory functions, other specified 
(Sensitivity to cold) 
 
b620   Urination functions 93.7 
  b6200  Urination  94.9 
  b6201  Frequency of urination  93.7 
  b6202  Urinary continence  98.7 
b640   Sexual functions 93.6 
  b6400  Functions of sexual arousal phase  77.9 
  b6403  Functions of sexual resolution phase  69.2 
b660   Procreation functions 67.1 
  b6700  Discomfort associated with sexual intercourse  88.5 
b710   Mobility of joint functions 80.8 
b730   Muscle power functions 87.3 
  b7303  Power of muscles in lower half of the body  87.3 
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ICF Code ICF Category Title Round 2              n=79 
2nd level 3rd level 4th level   % agreement 
  b7305  Power of muscles of the trunk  78.5 
b735   Muscle tone functions 93.7 
  b7350  Tone of isolated muscles and muscle groups 89.9 
  b7353  Tone of muscles of lower half of body  91.1 
  b7354  Tone of muscles of all limbs  91.1 
  b7355  Tone of muscles of trunk  86.1 
  b7356  Tone of all muscles of the body  88.6 
b740   Muscle endurance functions 77.2 
  b7401  Endurance of muscle groups  75.9 
b750   Motor reflex functions  
b760   Control of voluntary movement functions 91.1 
b765   Involuntary movement functions 89.9 
  b7650  Involuntary contractions of muscles   
  b7651  Tremor  96.2 
b770   Gait pattern functions 89.9 
b780  
 
Sensation related to muscles and movement 
functions 
 
  b7800  Sensation of muscle stiffness  96.2 
  b7801  Sensation of muscle spasm  97.5 
b810   Protective functions of the skin 62.8 
b840     Sensation related to the skin 93.7 
 
Body Structures 
ICF Code ICF Category Title Round 2   n=79 
2nd level 3rd level   % agreement 
s110  Structure of brain  
  s1106 Structure of cranial nerves  72.9 
s120  Spinal cord and related structures  
s610  Structure of urinary system  
s730  Structure of upper extremity  
s750  Structure of lower extremity  
s760  Structure of trunk  
s810   Structure of areas of skin 62.9 
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Activities & Participation 
ICF Code ICF Category Title Round 2   n=79 
2nd level 3rd level   % agreement 
d110  Watching   62.0 
d155  Acquiring skills  
d160  Focusing attention  
d163  Thinking   
d166  Reading 68.4 
d170  Writing  
d175  Solving problems   
d177  Making decisions  
d210  Undertaking a single task  
d220  Undertaking multiple tasks  
d230  Carrying out daily routine 82.1 
  d2303 Managing one's own activity level 78.5 
d240  Handling stress and other psychological demands  
  d2401 Handling stress 80.8 
d330  Speaking 75.9 
d335  Producing nonverbal messages  64.6 
d350  Conversation  
d360  Using communication devices and techniques  
d410  Changing basic body position 79.5 
  d4103 Sitting  79.5 
  d4104 Standing 81.0 
d415  Maintaining a body position  
  d4154 Maintaining a standing position  78.5 
d420  Transferring oneself 79.7 
d430  Lifting and carrying objects     
d440  Fine hand use 79.7 
d445  Hand and arm use 79.7 
d450  Walking 84.8 
  d4500 Walking short distances  83.5 
  d4501 Walking long distances  78.5 
d455  Moving around     
  d4551 Climbing 70.9 
  d4552 Running  68.4 
d460  Moving around in different locations 78.5 
  d4600 Moving around within the home 80.8 
  d4601 Moving around within buildings other than home 71.8 
  d4602 Moving around outside the home and other buildings 74.4 
d465  Moving around using equipment 75.9 
d470  Using transportation  74.4 
d475  Driving 80.5 
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ICF Code ICF Category Title Round 2   n=79 
2nd level 3rd level   % agreement 
  d4751 Driving motorized vehicles 82.1 
d510  Washing oneself 78.2 
  d5101 Washing whole body  74.7 
d520  Caring for body parts  
d530  Toileting  75.3 
  d5301 Regulating defecation  75.9 
d540  Dressing    73.4 
d550  Eating 78.2 
d560  Drinking 79.2 
d570  Looking after one’s health 84.6 
  d5701 Managing diet and fitness  80.5 
  d5702 Maintaining one's health  83.3 
d620  Acquisition of goods and services   
  d6200 Shopping  62.8 
d630  Preparing meals 64.1 
d640  Doing housework    68.8 
  d6402 Cleaning living area  65.8 
d650  Caring for household objects   
d660  Assisting others  
d710  Basic interpersonal interactions  
d720  Complex interpersonal interactions  
d750  Informal social relationships  
d760  Family relationships 75.3 
d770  Intimate relationships 70.5 
  d7702 Sexual relationships  72.7 
d825  Vocational training  
d830  Higher education  
d845  Acquiring, keeping and terminating a job 70.9 
  d8451 Maintaining a job 70.9 
d850  Remunerative employment 62.0 
d855  Non-remunerative employment 59.7 
d860  Basic economic transactions   
d870  Economic self-sufficiency  
d910  Community life  
d920  Recreation and leisure 64.9 
  d9201 Sports 59.7 
  d9204 Hobbies 55.3 
d930  Religion and spirituality 34.6 
  d9300 Organized religion 32.9 
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Environmental Factors 
ICF Code ICF Category Title Round 2   n=79 
2nd level 3rd level   % agreement 
  e1101 Drugs  88.6 
  e1108 Products or substances for personal consumption, other 
specified 
82.3 
e115  Products and technology for personal use in daily living  78.2 
  e1150 General products and technology for personal use in daily 
living 
59.0 
  e1151 Assistive products and technology for personal use in daily 
living 
89.9 
e120  Products and technology for personal indoor and outdoor 
mobility and transportation  
86.1 
  e1201 Assistive products and technology for personal indoor and 
outdoor mobility and transportation  
89.9 
e125  Products and technology for communication  
e135  Products and technology for employment 71.8 
e150  Design, construction and building products and technology of 
buildings for public use 
55.1 
e155  Design, construction and building products and technology of 
buildings for private use 
56.4 
e165  Assets 42.3 
  e2250 Temperature  58.2 
  e2251 Humidity  34.6 
  e2253 Precipitation  
  e2600 Indoor air quality  35.4 
e310  Immediate family 65.8 
e315  Extended family 46.8 
e320  Friends  
e325  Acquaintances, peers, colleagues, neighbours and 
community members 
53.2 
e330  People in positions of authority  
e340  Personal care providers and personal assistants 89.9 
e355  Health professionals 96.2 
e360  Other professionals 69.6 
e410  Individual attitudes of immediate family members  
e415  Individual attitudes of extended family members  
e420  Individual attitudes of friends  
e425  Individual attitudes of acquaintances, peers, colleagues, 
neighbours and community members 
 
e430  Individual attitudes of people in positions of authority  
e440  Individual attitudes of personal care providers and personal 
assistants 
 
e450  Individual attitudes of health professionals  
e460  Societal attitudes  
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ICF Code ICF Category Title Round 2   n=79 
2nd level 3rd level   % agreement 
e510  Services, systems and policies for the production of 
consumer goods 
53.2 
e525  Housing services, systems and policies 57.7 
e540  Transportation services, systems and policies 60.3 
  e5400 Transportation services 61.5 
e550  Legal services, systems and policies  
e555  Associations and organizational services, systems and 
policies 
65.8 
  e5550 Associations and organizational services 67.1 
e570  Social security services, systems and policies 70.5 
  e5700 Social security services 74.4 
e575  General social support services, systems and policies 64.9 
  e5750 General social support services 69.2 
e580  Health services, systems and policies 94.7 
  e5800 Health services 96.2 
e585  Education and training services, systems and policies  
e590  Labour and employment services, systems and policies 61.0 
  e5950 Political services 45.5 
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Personal Factors 
Answer Round 2   n=79 
  % agreement 
   
Coping 87.2 
   
Dependency from others / devices 88.5 
   
Loss of control 87.2 
   
Self-esteem 88.5 
   
Uncertainness about future 88.5 
   
Unrealistic therapeutic expectations 91.0 
 
nc - not classified 
Answer Round 2   n=79 
  % agreement 
   
Diagnostic and follow-up procedures (diagnosis, MS relapses, prognosis, disease 
course) 
96.2 
   
Use of adaptive devices 93.7 
   
Change of roles /role models 72.2 
   
Falls 94.4 
   
Information about MS 97.5 
   
Pregnancy planning 96.2 
   
Professional future 91.1 
   
Travelling with medications 92.4 
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hc – health conditions 
Answer Round 2   n=79 
  % agreement 
   
Depression 100.0 
   
Dementia 88.6 
   
Trigeminal neuralgia 93.7 
   
Epilepsy 86.1 
   
Oscillopsia 82.1 
   
Aspiration pneumonia 87.3 
   
Ileus and subileus 81.8 
   
Restless legs 82.3 
   
Psychotic disorders 83.5 
   
Osteoporosis 83.5 
 
 
 
 
 
 
 
 
 
 
 
 
